Annuc£l Report and Accounts For the year ending 31 March 2025 teno Registered Company No. 00943501 Regisiered Charity No.1054035 cancer care gofal cctnser Our year in numbers 5.242 81/ calls and emails handLed by our Support Line nurses Support Units bi the yedi eiiid Our Counselling service supported 544 people 934 16 of those received counseLLing through the medium of Welsh people regularLy attended our Sing with Us choirs Our Benefits Advice service, secvred £4.69xn worth of payments for peopLe with cancer 1.281 volunteers 200 events attended and talks given by our Community Engagement team £0.9m 250 56 raised from legacies participants iii our challenge events shop% in iommiJnities acros% Wales and EngLand Contents Chairfs and Chief Executive's ReporE Trustees Report (Intorporating Directors, and Strategic Reports) Cancer in context strategic aims What we achieved across our charitable activities Support Line Benefits Advice Service Counselling service Sing with Us choirs Mobile Support Units Community Engagement Campaigning for better outcomes for people affected by cancer Policy, Insight and Research Less SurvivabLe Cancers GynaecologicaL Cancers Vlorking in Partnership Our Income in 2024125 - Raising Money For Vital Support Community Fundraising Challenge events Individual Giving Trustr and Foundations 10 12 13 13 14 16 16 17 19 20 20 21 Gifts in WILLS 21 Ret by cancer to champion their needs, raise awareness of the issues faced and campaign to bring about change, at a national and community level. To be an effective, resourcefuL proactive charity where every staff member and voLunteer is dedicated to the work we do in supporting people affected by cancer. nnnnnnnnnnnnnnnnnnrynnnnnn What we achieved across our charitable activities We offer informcttion, advice, and specialist support to everyone affected by cancer. Our experienced nurses are here 365 dws a year to answer any questions about ccmcer. We c￿n help wi'th money worries cxnd pro￿de a safe spctce to tctlk (knout the emotional impctct of a diagnosis. We bring treatments closer to home, Cfnd our unique network of choirs are lun, friendly, ctnd uplifting. All our core services ure CDTailable bilingually in Welsh cmd English. This year. we've continued to embed knowledge of our hoListic service offer across the organisation, increasing internal referraLs and strengthening collaboration between teams. We've continued to develop new coLlaborative ways of working with our new advocacy work and extended benefits advice to HeaLth Boards. We WILI continue to expLore opportunities to maximise service reach through partnerships with other organisations, ensuring even more people benefi't from our support. seu tèn Jx"I Te.p,c.￿VJ Canfer c￿,(. Aiiriu¢il Rc.pori ond Accounis | YL'Jr èrioing 31 M.3:'ch 2025 Suppnrt Line Our Support Line reEncxins open 365 dctys a year to answer any questions ctnd get the right support, based on individual needs AvaiLabLe to anyone affected by cancer in WaLes and beyond, the Support Line is the door to aLI our services. We offer hoListic personalised support to people at all stages, from those worried about cancer to end of life care. Our online 'Ask the Nurse, 5eniice is avaiLabLe for people who prefer to write things down. This service is offered biLinguaLly in Welsh and English and other languages are available via a translation service. 5.242 calls and emails viere hcxndled by our Support Line nurses Cancer Callback Our CC￿cer Ccdlback service is ct series of proactive calls from one of our specidist •1 nurses foi people undergoing SACT (systemic cmti-cancer therapy). This unique service is delivered in partnership ￿th the NHS and c(cts as complementary trecttment support. We now support five Wetsh health boards: Betsi CadwaLadr, Hywel Dda, Swansea Bay, Cardiff & Vale, and Cwm Taf Morgannwg. This incLudes two cancer centres {Ysbyty Glan CLwyd and Singleton HospitaL) and seven cancer units {Ysbyty Gwynedd, Prince Phillip, GlangwiLi, Withybush, University HospitaL WaLes, Royal Gtamorgan, Prince Charles). We continue discu55ions with Aneurin Bevan HeaLth Board with a view to extend our service. Our nurses remain in constant contact across the above networks to sustain these retationships and to ensure referrals to our service remain high and as the numbers buiLd we have increased our team with an additional nurse to 5UPPOrt demand. During this year we have been in discussions with Velindre NHS Trust, and we WILI be piLoting an initial service for referraLs from Upper Gl and Hepatobiliary cancer nursing teams in 2025/26, The nurses liaise cLoseLy with the SA￿ triage units of each hospitaL to ensure full assessment of any post- SAC[ toxicities are undertaken. Our nurses continued to represent the organisation more wideLy by attending events and giving taLks to promote our expertise within the charity and to support peopLe affected by cancer in the best possible way. Tenows C2iiceK Caie A ￿1n￿31 Report and 4ccoiiii[f I lear l . I',I'.¢j , 2025 Bethan's- StorJ Beth receiv .support fro Nurses cmd enefits Advisors after being diagnosed with breast cancer crt just 26 years old. J}, Before her diagnosis, Beth was thriving. She was planning her wedding with fiancé Sam, excelLing in her role as a senior recruitment manager, and regularLy performing to full audiences as a taLented singer. Then came a devastating diagnosis. What followed was a whirlwind of surgery, radiotherapy, chemotherapy, fertiLity treatment, and emotionalturmiL That's where Tenovus Cancer Care stepped in. Through her treatment, our speciaList nurses kept in close contact, offering reassurance, information, and support. Meanwhile, our Benefits Advisors helped Beth navigate the complex weLfare system, ensuring she couLd access statutory sick pay and a Personal Independence Payment IPIP). Now, two years on, Beth is rebuilding her Life. Yenovus Cancer Care helped massively during the most difficult time& I'm leaming how to live again- and determined to get my life back. Tenth2Js Celncor Laie Aririual Report an(1 AccounL'. ' &ii Pi.:iii';u 31 Moir.h 2025 Benefits Advice. service A cancer diagnosis brings more thun emotional and physical chcdlenges - it can dso lead to signrficant financial strain. Combined with the ongoing cost of living crisis, many individuals and families continue to face overwhelming pressure. We heLp to guide, advise, and apply for benefits, grants and other financial and practical help peopLe with cancer may be entitLed to. Our advisors deaL with a significant number of clients each year, providing support to navigate the often-compLex welfare benefits system. AccessibLe and flexible, our service is mostly delivered remoteLy and includes Client Resource Packs that empower individuals to take proactive steps when they feeL ready. We maintain strong working relationships with the Department for Work and Pensions (DWP) and organisations like Capita, engaging at Local and nationaL levels to troubLeshoot issues, improve cLient outcomes, and help shape better processes and training within the organisations. This year, our insights have contributed to discussions around Universal Credit migration issues. Our triage function, led by an experienced adviser, has significantly reduced our waiting times and improved cLient satisfaction and is now 3 permanent part of our service modeL We have also embedded a dedicated Benefits Advisor role for C￿"ent5 Wlth an end-of-life prognosi5. This ensures fast-tracked access to support, including assistance with benefi'ts, WILLS, Power of Attorney, and funeraL planning - providing peace of mind at the most difficult time. The team has expanded its voLunteer support to two individuaLs: one assisting advisors by conducting outcome calls with clients. and another Leading a foodbank project, registering us with foodbanks used frequently by clients compiling a detailed referral step process. During the year we have collaborated to deliver benefits advice for Cardiff and the Vale University HeaLth Board and we are currently recruiting to support this initiative. In addition, we piLoted face-to-face session5 for patients of the Alaw Unit in Y5byty Gwynedd. This continues to be monitored with the aim of continuing in this Location. Tei1vV￿ Coyicer Care Annu21 Repoii A(coui:;' | Ye,Ir Ending 31 Maicli 2025 Counselling drvice A cancer diagnosis can crffect fctr more Together, we ensure that more people have access th￿n jusl physic￿1 hectlth. Thcrt s why our to the emotional support they need, when they specictlist Counselling service provides need it most. safe, conlidential spcxce lor individuals The development of our therapeutic counseLLing to talk openly about how cctncer is groups has been delayed due to a combination impacting their ]ives and to explore of process chaLLenges and low participant wh(]tever matters most to them. engagement. To heLp address this. we engaged an externaL consuLtant to advise on effective marketing strategies. This project has been temporariLy paused DeLivered by our team of highly trained, BACP- but WILL begin again in earLy May, following the registered counselLors, the service is available appointment of our new counseLLing manager bits'ngually in both WeLsh and English, ensuring that allowing this work to resume. everyone can express themseLves in the language they are most comfortable with. In November, we launched a referraL pathway in collaboration with Marie Curie's bereavement Our counsellors support people facing a wide range counselb'ng service. So far, this has included two of emotional chaLLenges. Common themes include four-week post-bereavement courses, with further anger, loneLiness, fear, bereavement, relationship development to be considered once our new strain, identity loss, and the difficulty of returning manager is in place. to work. Many clients express feeling unheard, overwhelmed, or uncertain about how to adapt to We have aLso seen growing externaL interest in Life during and after cancer treatment. We offer our counselling expertise, receiving requests from both one-to-one counseLling and virtual therapeutic extemal organisations to deliver 'managing difficult group sessions - bringing together peopLe with conversations. training. AdditionaLly, commercial shared concerns. organisations have approached us to explore potential staff webinars and training sessions. We have decided to evaLuate a pilot programme before determining the next steps for rolling out these opportunities more broadLy. ReferraLs to our service come through a variety of trusted partners, incLuding Health Boards across Wales and other charity partners. l•.J coun.-Itor understood enti rely what I was going through. I couLd tau< to someone independently of everyone else who knew me. and she vvas good. She advised me to make myself a priority, which was hard to do, but I knew I needed to put my own health fi'rst. To concentrate on me. - John Oui Counselling service supported 544 people. 16 of those received counselling through the medium of Welsh. Canccr Carc N.nnual Roport A(cou1i15 e&r Lndirbg 31 Varil 2024 Sing with Us choirs Music has the power to uplift and connect - and our Sing with Us choirs offer just thcxt for anyone crffected by c(xncer. Open to (￿, these choirs are fun, welcoming, ctnd supportive spctces where people come together to find joy, friendship, lind comfort through song. With support from our sessional choir Leaders, we've successfulLy met the rising demand for rehearsats and events. We're proud to have exceeded our target of10 performances per choir on average, although we continue to work around LogisticaL challenges in more rural areas. We continue to deveLop the voLunteer roLe in each choir, which is supported by reguLar training. This year. we aLso introduced a new initiative: Sing with Us Connect Events, run in colLaboration with our Community Engagement team. These sessions helped raise awareness of our wider services among choristers, encouraging them to access additional support such as counselLing, benefi'ts advice, and more. Over the past year, our16 choirs across Wales have continued to grow, weLcoming new and returning choristers each week. We've seen an increase not onLy in weekLy rehearsaL attendance, but also in the number of pubLic performances. Our data has been reviewed and updated giving us a more accurate picture, enabLing us to target recruitment accordingly. This data WILL now help us to implement a system of supportive caLLs to those who haven't attended choir for three months to check on their weLLbeing. My wife kept asking ine to go with her to choir practice, I was adamant I'd onLy go with her once, just to prove that I was willing to give it a go. Nine years Later. we are part of two Sing with Us choirs and sing at two LoveLight concerts every year. We hctve 935 active Sing with Us choristers lÉnovu¢ Cancer Care Annual Repoii ancl 4ccour I:, | Year Ending 31 Mai'ch 2025 Il tpno 'lenows Cancer Care Annual Report and Acc(H)n151 Year Ending 31 il Ik2025 10. Mobile Support Unit service Our Mobile Support Units demonstrate the power of innovation cJnd partnership in healthcare - bringing treatments for patients closer to home, whlle supporting the NH S to deliver more efficient, flexible services. Working in partnership with Local Health Boards and partners we provide treatments such as chemotherapy, immunotherapy, and Lymphoedema care from our fully equipped, hospitaL-standard mobiLe clinics. The team consistentLy ensure aLL our processes are up to date and compliant with current LegisLation so we can continue to dets'ver a high quaLity seniice to our partners and those affected by cancer. This year, we are thrilled our Units have continued to operate at maximum capacty across Wales. Highlights include: The expansion of our service model to four-days - a coltaboration with Vetindre NHS Trust and Lloyd5 Pharmacy CLinicaL Homecare - deLivering chemotherapy and immunotherapy treatments for cancer patients in the heart of the community. This saw average patient appointments increase from 90 to 260 per month. The feedback from the Trust is that the extra capacity is having a signifi'cant impact on their ability to provide SACT treatment to patients in a timeLy manner. It has aLLowed them to scaLe back on their reliance on additional clinics at the hospital that were being supported by staff overtime - thus reLieving pressure on NHS staff. A weekly head and neck cancer clinic for Cwm Taf Morgannwg UHB, part-funded by Faceup Cymru A bi-monthly Lymphoedema service with HyweL Dda UHB Continued support for PubLic Health Wales, diabetic eye screening programme, deLivered across Wales using two of our Units The long-term placement of our originaL unit at Bronglais HospitaL ensuring uninterrupted cancer treatment for patients while the hospitsL's oncology unit undergoes refurbishment We investigated the potentiaL provision for one of our Units to take part in a piLot for treating tung cancer patients. however this wasn't taken forward. TEriovLJS Cancer Care qnnual Repoi i and Accounis | Yea Enrling 31 Maich 20?.5 Community Engcxgement We recognise the importance of everyone affected by cancer h(rring access to the righl support. That's why we Launched our Community Engagement team in April 2023, to extend our reach and ensure our services are accessible, visible, and understood in every comer of WaLes. By the start of this year, a fuLL team was established including a senior Lead and Community Engagement Officers in both North and South WaLes. With additional funding, we aLso created a short-term Volunteer Manager roLe, helping us increase our A reach of over11,000 people through 200 volunteer base and expand our impact. events across the country This year, we proudLy supported 44 dedicated Our partnership with the Carers Trust in Swansea volunteers who helped amplify our work- from came to an end but this experience has helped to running stands at community centres to giving taLks guide the development of future offers. at LocaL events. Each volunteer receives fuLL training, and a designated team contact for ongoing support. Our preserbce in diverse communities helps raise A suite of new informative materials promoting awareness of our services. We remain committed our services have been developed and are being to building strong, inclusive connections and are distributed by the team. including posters displaying seeking continuation funding to sustain this vital services within community and healthcare settings. work into the future. Key achievements include: BuiLding a reLationship with One Voice Wales, leading to invitations to present at LocaL councils and community events Participation in 'Living WeLL' events hosted by Health Boards across WaLes Strengthened relationships with the farming community and Gypsy, Roma and Traveller (GRT) communities to improve access to cancer support nnd itr*•thL Wo belp. Cd brnaeh(m¥¥t achcw prydgr .ii•tm*s GqllwuJl •leh knIpu• IAr *.b I IEn*- -r?&Jf4Y41-Ji*¥ V¥kn¥ Cau our free Support Lina i N. uir.vll Gymtsmh i￿.￿TellI￿. Icnrn'uo Laire! Lare Annual Roport ariA Account: | Erid'"ng 31 kWa.-Ih 202 12. Campaigning for better outcomes for people a£fected by cczncer Polxcy. Insight and Research Making sure the experiences ol people The launch of a poetry book co-produced with an ALL- affected by cancer (Ire crt the he(ntt of Wales Cancer Community member made the event decision-making remains a core priority. especially memorable. The events are an annual We continue to advocate for chcTnge by fi'xture in our calendar, while we continue to maintain a dialogue with politicians around the benefits of engaging directly with policymakers, their constituents being invoLved in this work. amplrfying patient voices, and This year, we launched a new suite of self-advocacy highlighting the urgent need for improveo., resources - incLuding a GP checklist available in cancer services in Wales. muLtiple languages - shaped by the engagement team with the community and Wales-specific cancer In March, we launched our manifesto Losing data. This work ensures people across Wales can our Patience, setting out clear, evidence-based better navigate their cancer experience and access priorities for cancer care. Shared at major political the care they need. party conferences throughout 2025, the manifesto will shape our ongoing dialogue with eLected We have taken a strong stance against the UK representatives and manifesto teams in the lead- Government's October 2024 Budget decision to up to the 2026 Senedd elections. Through thi5 increase employer National Insurance contributions, work, we aim to influence the policy agenda and highlighting its damaging impact on the third sector. secure Lasting commitments to better outcomes for Despite limited engagement from Westminster, everyone affected by cancer in Wales. our campaign gained traction in the Senedd, where our correspondence was submitted to the Our Insight and Engagement team plays a vital roLe Finance Committee and featured by the BBC. in ensuring our work is evidence-led and centred Questions were subsequently raised in the chamber, around the experiences of people affected by cancer. prompting us to seek clarification from the Cabinet Through the AIL-Wales Cancer Comnmjnity - now Secretary for Health and Social Care and explore over 230 members strong- we continue to amplify potential mitigation support from the Welsh patient voices and drive meaningful involvement Government. across poLicy, seNice improvement, and research. In 2024-25, we shared 42 opportunities with the community, enabling members to shape external and internal decisions. Recruitment has been supported by national media coverage, events, and targeted social media. Positive feedback from stakehoLders highlights the value of involving real experiences in their work, and our partnerships with researchers continue to grow. Our Senedd event in June, themed around self- advocacy, brought together Ministers, MSS, community members, and our Sing with Us choirs. Although we have ceased direct research funding, we continue to track the impact of previously supported projects. This year saw at Least seven peer-reviewed publications arising from our past funding, including one featured in Nature. Topics ranged from genetics and diagnosis to cancer vaccine5 and incLusive research practices. We remain committed to ensuring patients and the pubLic influence research in Wales. Our ALL-Wales Cancer Community was credited in pubLications by Health Technology Wales on brachytherapy guidelines and in a report on the Lung heaLth check operational pilot, for which we aLso secured the funding. 13. Tencws Cancer Care AnnuBI Reporl 3ncl Accuvn(< | Year Endliig 31 March 2025 Less SurvAvable Cancers While we support everyone affected by cancer, our campaigning and poLicy work focuses where we can drive the greatest impact- tackLing inequaLities, improving outcomes for Less SUNivabLe cancers, ampLifying the voices of women affected by gynaecological cancers, and advocating for better ethnicity data collection. We continue to chair the WaLes Less SuNivable Cancer Taskforce, with a focus on six cancers with the poorest survivaL rates: lung, pancreatic, liver, brain, oesophageaL and stomach. We prioritised the cancers with the greatest potential for us to make a change in Wales: Lung, oesophageaL and stomach cancer. In January, we heLd a weLt-attended Senedd drop-in event, engaging with 20 Members of the Senedd and shared the powerfuL personal story of an oesophageal cancer patient. We also led media activity highlighting persistently poor one-year survival rates for peopLe with these cancers, reinforcing the urgent need for earLier diagnosis and improved treatment pathways. Lung cancer remains the Leading cause of cancer death in WaLes, and we continue to campaign for earlier detection through targeted screening. Over 5.000 people signed ourjoint Time for Targeted Lung Cancel Screening petition. which ended in April 2024, signaling strong public supporL We've since seen a shift in tone from Welsh Government, and scoping work is now underway via Public HeaLth Wales- where our Chief Executive now represents the third sector on the programme board. Our fringe event at the Welsh Labour Conference in November pLayed a key role in influencing the nationaL onversation. Dr Sinan Eccles, cLinical lead for lung screening, shared insights from the recent pilot and made the case for urgent action. The event was attended by the new Cabinet Secretary for HeaLth and SociaL Care, Jeremy Miles MS, whose subsequent statement to the Senedd confirmed he had brought forward advice on impLementation by six months - directly referencing our event a5 a key influence. We welcome this momentum and hope to see a final decision on a national lung screening programme before World Lung Cancer Day in August 2025. Building on the findings of our 2023 report A Burning Issue- which revealed that oesophageal and stomach cancers are uniqueLy underserved in Wales and that symptom awareness is alarmingly Low- we have continued to focus our efforts on improving outcomes. Our report remains a key piece of evidence in national conversations about the need to roll out new diagnostic technologies such as the capsule sponge test and transnasal endoscopy. We've worked closeLy with cLinical leaders, incLuding the new Upper Gl implementation lead Dr Hasan Haboubi. and provided input into the development of the capsule sponge service specification - launched at a dedicated awareness event in March. We aLso met with Joyce Watson MS at Ysbyty GLingwili in Carmarthen, aLongside the Upper Gl CLinical Nurse SpeciaList team, to gain first-hand insight into current service conditions and discuss opportunities for improvement. Our syrnptom awareness campaign, Life Shouldn't Be Hard to SwalLow, has been positively received by clinicians and stakehoLders. Its impact was recognised at a CRUK Early Diagnosis Conference and Action Against Heartburn UK event, particularly for its targeted approach through pharmacies and its focus on the most deprived communities. We are now working with OGCancer Nl to support the rollout of a similar campaign in Northern Iretand. SHOULDN'T SWALLOW ]f you have any questions about cancer, call our free Support tane on 0808 808 1010 For more information scan the code or rrisit our website o-t tenovuscancercare.org.uk teno cancer care golol LTJns@r Reg Charity No.1054015 I Carc. Ainuai Repori tsnG,IccourisJ | (ear Ending 31 ￿lar(h 2025 14. Cancer inequalities As well as our focus on the Less Survivable Cancer5, we are committed to caLLing out and taking action to tackle inequalities in cancer care and outcomes. This year we sat as a third sector representative on the WeLsh Index of MuLtiple Deprivation taskforce to ensure that cancer inequalities are adequately represented in how deprivation is measured. We continue to focus on gynaecoLogicaL cancers and the collection of ethnicity data from cancer patients as key policy areas. Ethnicity data In 2023-24, we identifi'ed a significant gap in the collection and reporting of ethnicity data within cancer care in WaLes - despite a mandate to do so. Throughout the year, we continued to press WeLsh Government to address this issue. In October, we met with the Head of the Anti-Racist WaLes ImpLementation Team and policy officials to discuss improving ethnicity data capture in the NHS. A key deveLopment came in January 2025, when it was confirmed that the new GP contract in Wales will incLude a requirement to record patient ethnicity. We WILI continue to engage with WeLsh Government and the BMA to ensure this is effectiveLy impLemented in practice. Working in Partnership Tenovus Cancer Care continues to play a Leading role in shaping cancer poLicy and service5 in Wales through our position as Chair and Secretariat of the Wales Cancer Alliance. We have contributed to the NHS Executive's Cancer Recovery Programme (2024-261, including securing third sector representation on the panel to appoint its new cLinicaL Lead. Following the Audit WaLes report on cancer care, we coordinated the ALLiance's response and secured public scrutiny through the Senedd's PubLic Accounts and Public Administration Committee, to which we gave evidence in March, Patient experience and cancer data remain central to our work. We champion the inclusion of the public and third sector in research conversations via the All-wales Cancer Community {AWCC), presenting our work at major events incLuding the Wales Cancer Research Centre and HeaLth and Care Research Wales conferences. We also contributed to the WaLes Cancer Insight Group and Cancer Industry Forum, and we continue to advocate for better access to validated cancer data for third settor use. We are awaiting access to a new secure data environment created specifi'caLLy for Tenovus Cancer Care. We wrote to the new First Minister and Cabinet Secretary for Health to highLight the need for urgent improvements in cancer care. This helped secure a meeting between officials and the WaLes subgroup of the Less SurvivabLe Cancer Taskforce, which is chaired by our chief executive, Judi Rhys. We engaged with the Older PeopLe's Commissioner's office and Cardiff CounciL to build reLationships and expLore collaboration and continue supporting the Welsh Index of MultipLe Deprivation Advisory Group, to ensure that the influence of health. specifically cancer, within the definition of deprivation is not overLooked. We met with key fi'gures from the WeLsh LocaL Government Association (WLGA), discussing topics from cancer care access to BLue Badge appLication inconsistencies. informed by insights from our Welfare Benefits Advisors. We met with the Leader of Conwy Council who is also the spokesperson for Health and Social Care at the WLGA, regarding our work in Conwy as well as getting an introduction into the work of the Health portfolio within the WLGA. At PLaid Cymru's conference, we shared our policy work and services, building reLationships with MSS and MPS. We also responded to WeLsh Government's draft Code of Practice for Funding, calling for better dialogue and implementation to support third sector sustainability. Through strategic partnerships and evidence-based policy work, we remain committed to improving cancer outcomes, championing patient voice, and ensuring data drives change acro55 Wales. Teriovu5 Lancer Care AnnuGI ReDO.'t and 31 March 2025 Gynaecologxcal cancers Our work to ensure that women's voices were centraLto the Senedd's GynaecoLogical Cancers Inquiry was recognised with a nomination at the Moondance Cancer Awards for Patient & PubLic Participation & InvoLvement. The resuLting report, Unheard, was debated in the Senedd in May. Ahead of the debate, we briefed Members of the Senedd with our response, outlining our concerns about the impLementation of the HeaLth Committee's recommendations. During the debate, the Cabinet Secretary for Health issued an apoLogy on behalf of the NHS. We continue to hold WeLsh Government and NHS WaLes to account for the commitments made during and after the inquiry. This includes pushing for action on accepted recommendations, as well as seeking further consideration of those that were initially rejected. Working alongside the late cancer campaigner, Claire O'shea, and Cavendish Cymru IformerLy Deryn), we supported the Launch of Claire's Campaign - a powerful platform amplifying the voices of women affected by gynaecological cancers. The campaign won UK Campaign of the Year- Beyond London at the 2025 PRCA Awards, setting a benchmark for peopLe-led advocacy in Wales. To maintain momentum, we coordinated a letter- signed by David Rees MS, Chair of the Cross-Party Group on Cancer- calling for a progress update from the Cabinet Secretary. We also wrote to RusselL George MS, Chair of the Senedd's Health and SociaL Care Committee, urging a short foLLow-up inquiry before the current Senedd term ends. In October, we responded to the draft NHS Women's HeaLth Plan, noting the absence of any reference to gynaecologicaL cancers. We secured a supplementary question from PLaid Cymru's DeLyth Jewell MS, to which the Cabinet Secretary responded. some of that thinking has certainly been shaped by Claire's Campaign.. We remain commL'tted to continuing this work, in pctrtnership vwith Claire's family cmd Cavendish Cymru, to make sure Claire's legacy hves on. Tenoius Lancc.r Care Annual Rokiorr dnd Accodni- | Veuf Eridii'ig 31 Mafih 2025 16. ".2019.115. Raising r support This year, we raised over £8.57 milLion in gross income (2023/24.. £9.65 miLLion), resulting in a net contribution of £2.8 milLion12023/24: £4.2 million) after deducting trading costs, as illustrated in the pie chart below. We Saw a decline in legacy income foLLowing the receipt of several exceptionaL legacies in the previous year. Despite ongoing economic challenges, both our fundraising and trading operations met their targets and continued to make a strong contribution to our overall h-nancial position. INVESTMENTS AND OTHER INCOME £146.218 CONTEIIBtJrIoNS FROM RET141L £223.500 NET CONTRIBUTIONS FROM OTHER TRADING £417.433 FUNDRAISING £1.191.788 £2.830.011 30% LEGACIES £851.072 Tenowi< Cancel Laie Ani)ual ReFoiI èiid 4ccoui,I:: '/(-dr Ending 31 Mr¥rcl", 2025 Key: Legacie£'. This is money that comes to us when someone kindly Leaves a gift in their WILL Net contribution from retail and other trading ctctivities: This is money raised through our shops, eBay channeL, and other commercial activities {after deducting the direct costs of these activities). Investments and Other Income: This is money earned through our investments portfoLio and income placed on other short-term deposits. FundrcJisincJ'. Money raised through donations, fundraisers and events, our corporate supporters, and partners. Our raffle activities fully comply with local council licensing that we have secured for the level of activities in this area. We remain committed to being responsible and respectful in our fundraising, and continue to be registered with the Fundraising Regulator. abiding by their code of practice and reguLations. During the year, as part of our aim to increase our Lottery players we agreed to face to face recruitment as part of our contract with Make a Smile, who manages and administers our lottery on our behaLf. We worked with them to ensure that a risk assessment was compLeted and the recruitment wa5 undertaken in accordance with our service LeveL Agreement detaiLing the fundraising standards we adhere to and expect. We have aLso reviewed and are taking steps to ensure adherence with the new code of conduct which WILI be introduced in November 2025. Despite the ongoing challenging economic environment, we had a successfuL year for fundraising and grew our income beyond legacies. Excluding legacies, we ended the year £300,000 ahead of budget and prior year. Many thanks to the incredible commitment of our supporters. leni)VUJ Canco.r Caio Annual He￿e.rI and 4cinunis | Year F.riding 31 Marc11 2025 18. Community Yundraising This year, our community fundraising continued We aLso saw success through major events Like to thrive, driven by the passion and generosity of the StrictLy Experience fundraising dinner, which supporters across Wales and beyond. We were proud raised £21,000 and heLped strengthen relationships to host another impactfuL Breast Cancer Awareness with ceLebrity supporters including professionaL Month campaign, with retail raising over £24,000, dancers including Kai Widdrington, Katya Jones, and alongside our groups hosting a series of local events presenter Matt Johnson. We are planning a similar across the country. Towns including LLandeilo and event in March 2026 to buiLd on this year's success. Penarth turned pink, and an abseil event in North Our Gourmet GoLf event generated £15,000, with WaLes attracted fantastic participation and energy. plans underway to expand to two events in 2025. We marked World Cancer Day with a Fashion Show Through our involvement in the Business Network hosted by broadcaster Sian Lloyd, raising £9,000. InternationaL {BNI) in Merthyr, we unlocked We continued to see creativity and community spirit valuable connections and raised a further £8,000 through events like two Pop-up shops in Ruthin, a in donations. Additionalty, our MobiLe Support Unit Jgby event at LLandybie RFC featuring Nigel Owens, showcase event, helped demonstrate the impact our and a fundraising dinner in LLandeilo with ceLebrity supporters have on our services. supporters. Our annual Lovelight Christmas concerts brought people together acros5 Wales and, for the first time, in London, helping raise over £20,000. Tea for Ten returned. buiLding on last year's success. This year, we were delighted to have the support of our patrons at a flagship event in Machynys, alongside many grassroots events hosted by our incredible supporters. Our Friends of Tenovus Cancer Care volunteer fundraising groups remain a cornerstone of our community fundraising, with a new group, Team Bertie, established in NewcastLe. We saw exciting growth in our internationaL fundraising, with the expansion of our work outside of Wales. This included the launch of the 'Cancer is Everyone's Business, committee, which is building strong networks in London and beyond. We were honoured to be named Charity of the Year by London Welsh Rugby CLub and CapeL y Borough and continued to benefit from our ongoing relationship with the London Welsh Centre. Further afieLd, we've developed new relationships, including with football commentator Bryn Law, who has run Leeds10K for us. We're immensely grcrteful to everyone who supported us this year - whether through organising an event, attending, donating, or simply spreading the word. Your contribution has helped us be there for even more people ctffected by cctncer. 11 txpf kl- Corporate partnerships continued to make a big difference. We are gratefuL for the support of organisations incLuding Berry Smith, Pure Cyber, Welsh Government, AshmoLe and Co Iwho raised over £IO.000}, Castell HowelL Eversheds, and No.I ReaL Estate. Our second St David's Day daffodiL event, held in partnership with Transport for Wales, spanned Swansea, Cardiff, and London railway Stations, raising £2,700 and increasing awareness of our work. io Tentsws Cancel Care Anriual Repoii and 4ccoui i) &ii Endirig 31 ￿lar=ll 2025 Challenge Lvents This year was a record-breaking year for our challenge events, with over 250 participants raising an incredibLe £194,000 to support people affected by cancer. Our Cardiff Half Marathon partnership continues to go from strength to strength. We grew our team from 70 to 100 runners in 2024, and pLans are already in pLace to more than tripLe that number to over 300 wnner5 in 2025. We atso saw record participation and fundraising at both Snowdon and IOYFan, two key fixtures in our challenges calendar. Our London Marathon team maintained its strong performance, continuing to bring in vital funds. Looking ahead, we are expanding our reach even further to incLude DubLin, Chicago, Tokyo, and Paris marathons, providing exciting new opportunities for our supporters to get invoLved and make a difference. Ire Individual ivxng We saw encouraging growth across our individual giving activities. Our Summer RaffLe was a success, generating over £8,000 - a significant increase on the previous year. Our Lottery, delivered in partnership with Make a Smile, also saw positive progress. For the first time since the pandemic, face-to-face recruitment resumed, alongside telesales and in-shop promotions. This muLti- channel approach contributed to a 90/0 increase in draw numbers, with 219 additional lines and a conversion rate of 32.50/0, exceeding our target. 1,690 Tenovus Cancer Care pLayers won, and the rolLover value increased to £25,000. rri Tenntruu Canrir Larc Annual Roporl Accouni.. | I'oar Ending 31 M3rch 2025 20. Trusts and Foundations Grants are an essential part of our income that help to sustain and to grow our charitabLe activities. Typically, we apply for funds for specific projects. This year, the support of the Moondance Foundation has been criticaL to deveLoping our counseLLing service, whitst WeLsh Government, the Stjames's Place Charitsble Foundation and the ScottishPower Foundation - in particular- provided important funding towards our Benefits Advice team. The year aLso saw the conclusion of an important grant towards the Mobile Support Units from the GarfieLd Weston Foundation, ptus two UK Shared Prosperity Fund (UKSPF) awards- Cynnal y Cardi and Community and Voluntary Support Conwy- towards our Cardigan and Lampeter, and Conwy and Llandudno shops respectively. In addition, the successful deveLopment of the Community Champions volunteer programme took place thanks to a VoLunteering Wales Main Grant administered by the WCVK Speaking of community programmes, the Shaw Foundation and Hodge Foundation provided vitaL funding to grow the Community Engagement team, with the Hodge Foundation also kindLy supporting the development of Cancer Callback. Gifts in Wills The generosity of peopLe who choose to leave a gift in their Will continues to make an incredibLe and lasting impact on our work. These special donations heLp ensure that we can be there for future generations affected by cancer. This year, we saw another strong performance from our Free Wills Month campaign, with over 1,000 Wills offered - a continued year-on-year increase for the fourth consecutive year. So far, £870,000 has been pledged through this ccxmpc(ign. This income is vitcd to our long-term sustaincxbility. 21. TeiitWLlS Cancer CcrE AnnLI-l Rep?112nd Accniiillk | YLai Eiioinq 31 Nliaicli 2025 Retail Our network of 56 shops continued to generate ranges incLuding Welsh manufactured products. a substantial income for the charity thanks to our This activity has heLped to grow our database, and dedicated staff and fantastic team of over 900 our products have featured in over 20 mainstream volunteers who play such an important part in newspapers and magazines. We would like to running them. Despite the challenges all retailers especialLy thank our suppliers for their support faced on the high street we have successfully during the past year. generated a net contribution of £223,500. Recognising the need to innovate and improve, We continued with our strategic aim to invest in our we decided to use the opportunity to tender for premises deLivering successful refits in Llangefni, a new suppLier for our Christmas cards and after Barmouth, Romsey, Tetbury, Cardigan, Lampeter, a successfuL process, we WILL be moving to a new Merttyr TydfiL and Conwy, with grants obtained supplier for Christmas 2025. The change will enable towards the costs in Cardigan, Lampeter and Conwy. us to maintaln a competitive prlce point and profit Despite the continued support of our staff and margin, and more importantLy move away from any volunteers, it remained operationally difficvlt plastic packaging. We WILL also be introducing a new keeping all our shops trading six days a week, card range that WILI feature locaL scene5 to test the market. particularly in EngLand. We continued triaLing new methods to overcome the problem with some Our three Centres of Excellence Launched Last year success. Income was further impacted by stwctural to provide bespoke training and inductions to our issues in our Devizes shop, and it was unable retail teams continue to prove very successful by to trade for eight months, with us continuing a improving retention rates and training success and presence here having to trade from a temporary we wilL look to expand these to be able to cover a location. We are grateful to our staff, volunteers wider geographical area, particuLarLy in EngLand. and communities who have continued to support us through these difficuLt times. We intended to roll out a new EPOS system in the fi.nal quarter of the financialyear, however there Our physicaL eBay operation continued to grow with was significantLy more work invoLved with this than the addition of new volunteers to support the staff anticipated. After a tender process, we seLected and the successful expansion of the eBay operation our EPOS SupP￿"er, and planning work is well under into the Flint and Cowbridge shops. We have a way. In the early part of next financial year we have plan to roLI out into more shops in the coming year. 9 pilot shops which WILI go Live in May, with the Our online shop continues to improve and has remainder of the shop network following in June been especiaLly successfuL in increasing its product and JULY 2025. •• .tfif171, tenorf) vo Tcno%US Lancor Larc Annual Report and Accounrs | Yoor Ending 31 March 2025 22. Supporting our people We continue to support flexible and hybrid working arrangements, enabling our stcrff to work effectively ￿crOsS Wales while making the most of our centrally located Cardiff olfice cts a collcTborative hub. This year, we Launched our new organisational vaLues and used staff focus groups to gather feedback and co-create a new action plan to further improve employee experience. We aLso successfuLly roLled out our new HR and payroLL system, POBL, streamLining processes and empowering staff to manage their own data. with ongoing work to enhance how we work across teams. Learning and development remain a core priority. We delivered leadership training covering coaching, delegation, and giving feedback, alongside performance management, risk assessment and accident investigation, and Strategic development training for senior leaders. Our retaiL team aLso undertook Violence and Aggression training, while our helpLine team received targeted training in supportive communication skiLLs. We continue to provide a 2417 Employee Assistance Programme for all staff, and our internal digital communications ensure coLLeagues remaln informed and engaged. Our voLunteer community remains central to our work. with over 1,100 individuals supporting us across shops, fundraising. support services, and head office functions. This year, we worked to improve the incLusivity and overaLL experience of our volunteers - reviewing and updating our VoLunteer Recognition Policy based on voLunteer feedback, designing a new weLcome pack, and hosting our annuaL Volunteer Awards to ceLebrate their invaluabLe contributions. TEll￿rENOvUs 23. T61i0vuc Cancer Care A￿nUal Repoil and Ac(ounis l Year Ending 31 Maril) 2025 Janafa volunteers for 3 hours a week at our Neath shop, which has helped her confi'dence and her communication skiLIs "I really enjoy being at the shop. Not only has it boosted my confidence and improved my English, but it also added an extra dimension to my lrfe beyond the responsibilities of being a busy motherto two children." Tenok'u¢ Cin(er Lr*re Annual RokN)ri ￿1)d ilrcourbt: 'leJr Ending 31 Morch 2025 24. ProtectAng our supporters We remain committed to ensuring everyone who engages with us - whether as a supporter, volunteer, service user, or staff member- feels respected, protected, and free from undue influence. As members of the Fundraising ReguLator, we adhere to its Code of Conduct and uphold the highest standards of ethicaL practice in aLI our fundraising and service delivery. This year, we prioritised staff and sUPPOrter safety through a comprehensive safeguarding programme. AIL staff completed training in line with the National Safeguarding Training, Learning and Development Standards in Wales, and we conducted a fuLI review of roles requiring DBS checks, aLongside fuLfilling all mandatory health and safety requirements. We received 5 compLaints across our retail portfoLio in relation to staff conduct, accepting and pricing of stock within our shops and one instance in reLation to a window display. One further investigated compLaint re the use of Language on an individual's social media was outside our control as they had not been employed by us for a significant amount of time. In aLL cases the complaints were investigated with feedback to staff and the complainants with process amendments if required. We reported two serious incidents to the Charity Commission: an internaL data breach and a case invoLving sexuaL harassment with the latter being reported from one of the retail compLaints above. In totaL, we received nine safeguarding reports covering a range of concerns, including chiLd sex offenders attending choir5, Staff mental health concerns, a seniice user with suicidal thoughts, and a further report of sexual harassment. We aLso received seven volunteer-related compLaints incLuding Iwo reLating to support services. Each of these reports was addressed through appropriate protocoLs and, where necessary, escaLated to external agencies. Technology This year marked signifi'cant progress in strengthening our technological infrastructure to better support staff, streamLine processes, and improve data management across the organisation. We as515ted in the roLLout of the new HR and PayroLL system, PobL improving efficiency across our people management processes. In retaiL, preparations for the introduction of a new EPOS system began, with implementation continuing into the next financial year. We brought our warehouse team fuLLy online through the instaLLation of an updated Wi-Fi solution. Within IT, we successfully implemented a range of monitoring tools to provide fuLL visibility over our Systems, including data usage and storage. These developments have enhanced user experience and are a criticaL step in our preparations to achieve Cyber EssentiaLs Plus accreditation in the near future. We continued to focus on the quaLity and accuracy of the dats we hold. A key area of work has been reviewing and restructuring processes retated to our two main software pLatform5, used by our fundraising and support services teams. This work is ongoing, and the changes are designed to improve the accuracy arbd timeLiness of data reporting. While our goal remains to produce management reporting dashboards, this year, we dedicated time to refi'ning the underLying data structures before we integrate these systems. 25. Tenovus Lancer Care Aniiual Repoi l arid 4ccouiii£ | Yf ar Eiiuing 31 March 2025 Promoting Equality. Diversity and Inclusion We want Tenovus Cancer Care to be an incLusive organisation where everyone feels weLcome and free to be themselves - whether they are affected by cancer, a voLunteer, supporter, or staff member. Our commitment to inclusivity is embedded in our newLy revised values and across aLI areas of our work, incLuding service delivery, recruitment, voLunteering, and engagement. This year, we continued implementing our Cultural Competence Action Plan and maintained our status as a DisabiLity Confi'dent Employer. Our internal EDI working group, with representation from aLI departments, drives progress and shares best practice organi5ation-wide. Over 75 employees have received EDI and unconscious bias training with Diverse Cymru and all new starters compLete EDI training as part of their induction. We've improved data monitoring to inform policy and improve seNice provision across our services, gathering voluntary equality information from client5 on our Support Line, Benefits Advice service, and Sing with Us choirs. In the finaL quarter alone, 47% of new choristers provided monitoring data. At present, we onLy ask for this data at one point in the client journey, and we do not chase non-responders as we do not want to increase the burden on our clients. However, we WILL review our methods to expLore ways to increase the response rates from clients. Staff are aLso encouraged to compLete EDI data in our new HR system, with alL data reviewed annually and benchmarked against the WaLes average, to identify gaps and assist with future recruitment opportunities. We took a snapshot of data across our voLunteers to focus on the development of the volunteer offering. EDI remains a prominent focus when recruiting incLuding incLusivejob advertisements, use of a gender decoder to ensure neutraLity and a fLexibLe and professionaL approach to interviews by recruitment panels. To better refLect and engage diverse communities, we have adapted volunteer resources to be more accessible, incLuding ea5y-read training materiats. We shared stories from underrepresented communities during Volunteers Week and promoted them externally to boost inclusive recruitment. Our commitment to the LGBTQIA+ community continues through the taunch of an internal staff nebNork and participation in Pride events across WaLes, including performances by our choirs. We also remain proud of our bilingual services. We have continued to deveLop and embed our 'Cynnig Cymraeg, across the organisation. Our Grwp Cymraeg meets reguLarLy to maintain and improve our Welsh language provision, and we now colLect language preference at referraL to help match clients with Welsh- speaking staff where possible. We encourage staff and volunteers to use the Language at work and, this year, introduced a regular Paned a Sgwrs event as a space for people to prartice their Welsh and connect with others. Caneer d 'If L--l Hepori and Accouni,- | Yeidr Èndirig 31 fvlarc.. 202, 2e. Money spent on our services 2024125 Our chcTritable expenditure amounted to nearly £2.6m (2023124: £2.25m) nd we hctve focused this spend on Policy & Insight, growing the community engagement te(xm and continuing with our other services pro￿'s1On as per our strategy. We continue to mcxke advances in providing support without significcmdy increasing controllctble costs, ensuring our procedures are efficient to complement this drive. MOBILE SUPPORT UNITS £567.713 RESEARCH, POUCY AND INSIGHT £379.143 15 ENGAGEmE￿r £198.143 COUNSELIJNG SERVICE £392.424 £2.552.496 15y. Il% SUPPORT LINE £290.432 15 BENE￿s ADVICE SERVICE £351.699 SING WITH US £372.942 27. Tell￿￿￿< Caiice Caie 411!IUts'l RtDoiI alli 4iiuu' IiidiiiL) 31 MaiLII £02) Managing our osts In this year we have continued to manage our cost base to use our generated income on our services as effectively as we can. We compLeted planned retaiL refurbishment expenditure and continued capitaL expenditure across IT to match against income receipts ensuring that we have adequate cash resources to underpin our ongoing activities. We continue to use our tender process to review the value for money of significant costs that we incur and to ensure that we receive a comprehensive competitive service from our key suppLiers. Investments Our fixed asset investment portfoLio continues to be used to support ongoing activities and to maintain capital to support our future work. The income from our portfolio when not reinvested is used alongside our other income-generating activities to support the charitable work. We have given BarcLays Wealth {regulated by Fin3nciaL Services Authority) discretionary powers to manage a balanced portfolio to achieve this. Our portfolio responded weLL across both the equities and bonds held for the bulk of the year resulting in an increase in the vaLue of the portfolio to £5.4m (£4.9m.' 2023/241 at the end of the fi'nanciaL year. This has generated realised gains of £3,463 (2023124: £78,130 gains) principaLly due to maintenance of funds held from the previous year to this year with a Large percentage heLd on the American market and noting a £400k addition to the portfolio. At the year-end we recorded unreaLised gains of £64,226 {2023/24.' £322,805 gains) - excLuding currency differences - refLecting the impact of the general market reaction to gLobaL trade tariffs announced around the year-end valuation of our portfolio. Both gains have been charged on our unrestricted reserves. Our policy is to not direttiy invest in any stocks or shares associated with the tobacco industry. The trustees are mindfuL of the need for a balanced portfoLio and reguLarly monitor the performance via delegated authority to the Finance, Audit & Risk Committee. Following discussions with BarcLays Wealth, a decision has been made to move the existing portfolio into a SustainabLe TotaL Return Fund for Charities with a medium risk attitude applied to this fund investment. The decision has been taken to ensure that we continue to invest in areas aligned with the charity objectives, to achieve an equaL LeveL of return to that currentLy received but to meet our aim to invest sustainably and ethicaLly across the investments we are making, specificaLLy Looking to achieve against the UN Sustainable Development Goals. This move to a new fund WILI aLLow us to achieve this and we will aim to have our fund transferred by the end of quarter one next year. The details of our investments can be noted on pages 68 and 69. (Defxcit)/ Surplus in Year With the money raised this year through all sources that we have received against the money spent on support services we have generated a deficit before investment gains of £985,34012023/24: surplus £858,239). This defi'cit has been LargeLy charged through our unrestricted reserves with some to our designated funds in accordance with our reserves poLicy. We continued the retaiL refvrbi5hments that we had scheduled during the year, increasing the charge to this fund. IT upgrades continued as weLL as increasing spend on charitabLe expenditure. This was against a backdrop of lower-than-expected legacy income receipts in the year but aLso from retaiL continuing to perform in a difficult market, with the overaLL deficit remaining within our predictions. This 15 noted on page 41 within our reserves policy and within note 22 detaiLing the fund movements. '10f￿?l,l￿ Lr*dllC￿r Laro Anriual Rc.p(Iri dlli.1 I'i>iiril | Year Ending 3114-It*T{h 2025 28. Looking lorward We rem(xin committed to our vision of u future that gives everyone alfected by •1 cancer, in Wcdes (￿d beyond, the best access to treatment and support they need. Strategic Aim I: To provide cancer support, information and services that empower and encourage people, helping them to hcNe an improved quality of life. Across all our charitable activities we will: Continue to build relationships with the NHS and other stakeholders across Wales to raise awareness of our services and the referral process. Through our holistic approach working with partners, where appropriate, we aim to ensure the full range of needs for individuals are met. Continue to improve and refine our ability to present accurate data to our colleagues, Board of trustees and partners across Wales. Respond to any changes in the externaL environment and adjust our service delivery accordingLy. Work collaborativeLy across all departments so that the extent of our seNice offers is clearly represented to aLL Support Line Continue to Look to achieve a partnership with Aneurin Bevan University Health Board to offer a holistic Cancer CaLlback service. Sustain existing relationships with NHS to maintain referral levels, including monitoring the uptake of the service offer in VeLindre and the capacity to expand the number of clinicaL teams we can sUPPQrt there. Pilot an initial service for referrals from Upper Gl and HepatobiLiary cancer nursing teams. Benefits Advice Creation of two senior advisor roles within the Benefits Advice team to continue the operationaL responsibiLities supporting the current Advice Services Manager who wilL be developing the advocacy support. New voLunteer role to provide support to the new advocacy Lead to refresh our internaL directory for signposting and develop Links to other directories to avoid duplication. Develop services in Betsi Cadwalder and Cardiff and Vale University Health Boards reflecting increased funding. Feed into any specific policy asks in respect of forthcoming changes to the benefits system to high￿.ght the impact on people affected by cancer, as well as developing our work around highlighting discrepancies in Blue Badge application processes across Wales. Monitoring sessions at ALaw Unit in Ysbyty Gwnedd to consider its ongoing delivery. 29. Tenovus Cancel Care AIiiu41 Repoii and 4ccouiii! | Year Endiiiq 31 March 2025 Counselling DeveLop and deLiver the virtual group offer with support from marketing experts and other partners. Consider the extension of the referral pathway in collaboration with Marie Curie's bereavement counselling service. EvaLuate our pilot programme for feasibility to assist external organisations to deLiver 'managing difficult conversations, training and to expLore potential staff webinars and training sessions. Sing with Us Choirs Instigate a connect event for12 choirs to attend during the year. Continue to build chorister numbers within the smaller choirs and recruit choristers across the country. Reinforce the volunteer roLe across all choirs. Maximise performance opportunities in coLLaboration with choristers to provide a quaLity experience. Using cleansed data, implement a system of supportive caLLs to those who don't attend choir for a period of three months to check on their wellbeing. Mobile Support Units Agree continuation of service deLivery for NHS screening programmes over the Longer term. Continue to investigate any opportunities with the NHS and other partners to maximise usage of the MobiLe Support Units. Maintain our high-quaLity provision and explore any ways in which efficiencies can be made. Community Engagement Continuing to work with our committed voLunteers to support the service with the aim of expanding the numbers in North WaLes to match number5 in the South. Continue to publicise our services througlK)ut the communities to aLLow peopLe to seek our support when needed. Increase reach and tiaise with other organisations where our aims can be met in the communities of Wales. Focus on diverse groups and communities who do not traditionally engage with us and develop a pathway to improve access for these groups. Focus our presence on communitie5 that have high deprivation and cancer incidence. Advocucy Support Seek to launch an Advocacy offer overseen by our Senior Advice and Advocacy manager to deveLop a strong referraL re￿tionship with a cancer-specific advocate at Llais for those who feeLthey haven't received the best care and support. Scope existing provisions and define the parameters of the offer to create a framework to enhance existing seLf-advocacy tools developed over the last year. I r-Ti Tracey Burke (Chairl Irort Christopher Thomson IDepLty Chairl Timothy Finch (appointed to Chair of People Committee13 November 2024. Louise Fleet Iresigned16 October 241 Huw George (stepped down a5 Chair of Finance Audit and Risk l March 251 CaroLine Bovey Natasha de Teran Prof Jane Hopkinson Dr Lucy 5witherbank ALun LLoyd (Chair of Finance Audit and Risk from l March 251 Independent Advisor Amy Lord 33. TennkLl¢ Caacei Care Ani)U&il Repoi'i and Accoui)t< | i'eai Ending 31 March 2025 Our Patrons Royal Patron HRH The Princess Royal Rob Brydon Mike Bubbins Aled Davies Amy Dowden Curl Edwards Wynne Ev.cms Connie Pisher Dafydd larnes Hcmnah Jones IC￿ Uoyd Rupert Moon Nigel Owens Leona VuLiqlictn lenovua LancoT Ldro Anriual Ro" ort and Accniinis | Yedi kndir..g 31 Ma.'ch 2025 34. Leadership Team Chief Executive Judi Rhys MBE Hazel Sweeney FCA CTA D(xrren Irwin Director of Finance Director of Income Generation. Marketing and Communiccttions Director ol People and Development Julie Rees Director ol Support. Policy. Lowri Griffiihs and Insight Comp(xny Secretary Hazel Sweeney FCA, CTA Principal Address and Registered Ollice 1st Hoor, Jones Court, Womanby Street, Ccxrdrff CFIO IBR Telephone: 029 2076 8850 Principal Professional Advisors and External Auditors Advant(Jge Accountancy and Advisory Ltd, Avalon House, 5-1 Cathedral Road, Cardiff CFI19HA Solicitors Berry Smiih, Hcrywood House, Dumfries Place, Cardiff CFI 0 3GA Bankers HSBC Bank plc, 56 Queen Street, Cardilt CFI 0 2PX Investment Advisors B(xrclays Wealth, 4th Floor, Bridgewcxter House, Counterslip, Finzels Reach, Bristol BS16BX 35. Tenoviis Caiicer Cale Annual Report 2nd Accounis l Year Ending 31 Nliar(h 2025 Subsxdiary Undertaking Finance Audit and Risk Committee Tenovus Cancer Care has one wholly owned subsidiary, Tenovus Trading Limited. The company shares its registered office with Tenovus Cancer Care. The Committee forms part of the overaLL governance arrangements and takes delegated responsibits.ty on behalf of the Board of Trustees for overseeing alL financial aspects of the charity so as to ensure Long term viability, including: financial and operational performance and procedures annuaL ptans and budgets investments Tenovus Trading Limited conducts trading activities, such as greetings cards and other purchased goods for sale in Tenovus Cancer Care shops and at events, an online shopping site and the use of Mobile Support Units for non-cancer seniices, with aLI profi'ts being covenanted to Tenovus Cancer Care. The results and year-end position of the subsidiary are shown in note 3a to the fi'nancial statements. pensions poLicies and processes for the identifi'cation, assessment and management of risk, including financial controL The Board The Board of Trustees is responsibLe for the overaLI governance of Tenovus Cancer Care. The trustees as members are aLso Directors of Tenovus Cancer Care. As set out in the Memorandum and Articles of Association, the Chair of Trustees is nominated by the Board of Trustees and elected by them. the charity's financiaL statements to assess the integrity of financial reporting the scope, resuLts, and effectiveness of external and any internaL audit the independence of the externaL auditors, their range of non-audit services and fees. New trustees are appointed following a seLettion process using a number of methods. When recruiting new trustees, the Board considers the specialist skiLI identified through a skills audit. New trustees are appointed by majority vote from the Board of Trustees, initialLy for a period of three years, but may be invited to serve for a further three-year term. New trustees are provided with an induction, giving them an oveNiew of the responsibiLities and activities carried out by the charity. Training on external and organisational issues is provided as required. People Committee The Committee takes delegated responsibility on behalf of the Board of Trustees for appointing and inducting new trustees as weLL as monitoring and reviewing the composition skilL set and experience of trustees. The Committee WILL also deveLop a remuneration poLicy to attract, retain and motivate those people of the highest calibre who have the skills needed to achieve the charity's objectives at Director level including the Chief Executive. The Board of Trustees and Executive Directors meet at Least four times a year, and as members at an Annual GeneraL Meeting, and are responsibLe for setting an appropriate strategy for the charity. The Board also ensures that relevant performance measures are in pLace, receiving regular reports on all aspects of the charity s work. The Committee will aLso provide assurance to the Board on all matters reLating to staff and voLunteers including employee relations, safeguarding, health and safety, equality and diversity. The responsibilities of the People Committee are to: There are now two committees, one sub- committee, with the former research committees and group now disbanded. The members of the Committees include trustees meeting with Executive Dirertors and are also attended by external advisors when required. The Terms of Reference for these Committees are summarised beLow. carry out regutar skills audits of the Trustee Board and identify the skills, experience, characteristics, and backgrounds needed to provide high quality effective governance as well as appropriate chaLLenge and support to the Chief Executive len11￿~￿￿ Cancer Care Annual Report anil Acrounra | Year Ending 31 March 2025 36. prepare role descriptions, person specifications Psyehosocial Research and an information pack for prospective Board members and prepare a recruitment plan and Ildvisory and Scientilic timetabLe Advxsory Sub Commxttees and Research Sub Group interview prospective Board members and as appropriate recommend the appointment of candidates to the Board consider and recommend to the Board the broad poLicy for the remuneration of the Chief Executive and Directors These Sub Committees and Group were disbanded at the end of Last year after the completion of the finaL reviews. We wouLd like to thank alL the contributors for their support. be responsible for selecting and appointing any remuneration consultants who advise the Committee Chxef Executive ensure an ongoing programme of board development. including technical and other briefi'ng sessions, away day5 etc establish and regularly review the charity's remuneration policy and advise the Board of Trustees on remuneration and salary reviews including employee benefits agree standards and procedure for terms and conditions of employment and grievance and disciplinary procedures incLuding the monitoring and maintenance of these standards and procedures support the Board on staff and voLunteer issues oversee and seek assurances of the appropriate values and culture Authority to conduct Tenovus Cancer Care's day- to- day activities is delegated to the Chief Executive, who is responsible for ensuring the Board strategy and poLicies are carried out. The Leadership Team reports to the Chief Executive and meets monthLy. Corpor¢rte Governance The trustees continue to complete an annual review against the latest charity governance code to highLight any areas for potential improvement. This is used to deveLop the charity's future policies and internal procedures, to ensure we continue to fottow best practice. consider such other matters as are referred to the Committee by the Board Senxor Perlormance and Remuneration Sub Committee The Sub Committee is responsible for the remuneration packages of the Leadership Team and Chief Executive and reports their recommendations into the People Committee. 37. Cancer Care -%,, Repori and Accouit¢ | Ye?1 Endiiig 31 March 2025 Risks The risks the Board monitors have been defined across the foLlowing categories with the responsibiLity of ongoing review and management noted as: Bourd ReweThT: strategic and governance reputationaL environmentaL and external - in(Jnrp (y.nd Ai.Idit: compLiance and regulatory review fi'nanciaL We have spent time this year understanding the impact of climate change and sustainability as noted below. WhiLst Artiticial InteLLigence remains on our radar, we will be Looking to achieve a fvLler assessment of this once we have embedded work around a number of the other risks faced. The key identitiabLe risks that the charity face with an overview of the work to mitigate these when possible have been summari5ed as: Risks Identified for Board Man(xgement across Str(rtegic and Governance, Repututional ctnd Environmental and Externctl Categories,. RED IUSKS Nothing further identified during the current year with work undertaken to mitigate previous risks in this category to re-categorise these. AMBEII FUSKS Ongoing World Events - impacting on service delivery We continue to monitor the impact of the changes in the GLobaL economy resulting from conflict and trade discussions and subsequent impact to the UK economy. This continues to impact our ability to raise money due to pressure on aLL parties, disposable income as weLL as the impact of direct tax increases on the charity as an employer. We have noted the ongoing c05t5 for our staff and volunteers of traveL and we will continue to facilitate hybrid working where this is possibLe. We continue to monitor the effect on staff retention, and this continues to be considered within our pay review awards. lenobuJ L2nior (are Annual Roporl and Accounts | Year Endina 31 M&fch 2025 38. AMBER RISKS Failure to secure relicxble sustcxinable income with an over reliance on a few income streams We continuously monitor income generation against the strategic income plan presented by the Director of Income Generation, Marketing and Communications. Legacy Settlement remains SLOW with probate courts stiLI tackling backLogs and we have seen an increase in our work particuLarLy on more complex property cases received. During the current year we have faced a continual shift in the retail landscape against a challenging backdrop from the current economic climate, with us having to review and adapt at a rapid pace. The gLobaL economic situation and the impact on our investment portfolio continues to be monitored. Clear tracking of the income in reLation to what we can spend remains key to achieving against the income generation strategy timeLine. We have once again taken into consideration the gLobaL economic position and in particular the impact on retail when setting our budgets and the ongoing investment around Legacies to support our income growth. Change Management of Projects and Actiwties During the year, a project manager was appointed to manage the three key projects that the Charity is focusing on to deliver change and improve efficiencies. These affect all areas of the charity and therefore continues to be monitored. Departure of our CEO Tiidi Rhyg Considerations around recruitment for this role have been noted for action this year to effectively manage the transition to a new CEO in the next financialyear. Climate Change and Sustciinability An initial review of risks from external cLimate change and likely impact across the charity have been compLeted. An action pLan for mitigation where possible is now in progress. Regarding sustainability, we are working towards what changes we can make across the charity to improve sustainability and minimise the charity impact where we can have been recognised. Ongoing work over the next few years will look to establish what Steps we have taken and how we can report on this, beginning with any new contracts that we undertake. These have been noted a5 risk5. but the Board is confi'dent of the controls and ongoing actions that are currentLy in pLace across these areas. Failure to attrart, recruit and retain the right staff and volunteers for key posts across the organisation Failure to follow legisLation that we are governed by. Fraud within the charity. Cyber Security. 39. Teiiovus ( uilQ&i CJI v Arinual Repuri ai)Ll Accoui Il.. . 31 MaiL.'12025 Policies Management ol reserves Our income is made up of both retaiL and fundraising income incLuding legacies. We recorded a deficit in the year on our unrestricted generaL fund (before investments) of £0.92m {2023/24: surplus £0.89ml, taking our overaLI unrestricted general fund reserve this year to £5.32m (2023/24: £6.12m). The deficit represented the ongoing expenditure this year on activities noted in our report. As trustees we look to hoLd adequate reserves for the charity. This allows US to react to continued chaLLenging economic times, future liabilities and potential threats as well as unexpected opportunities, in order to provide our services for the medium-to long term. We baLance this with spending the maximum amount that is financially pwdent in order to achieve our aim of delivering charitabLe activity in the shorter term. The calcuLation of the required LeveL of policy reserves against identified risks and required expenditure to achieve this, is an integral part of our annual planning, budgeting and forecasting cycLe. We continue to see unpredictability in concluding legacy settLements, as a result of the backlogs faced by the probate courts which impacts on short term cash flow. This is needed to deliver our seNices and continue with our strategic pLan to deliver an increase in our charitabLe spend particvlarLy within our community offering, supporting and highlighting those less survivable cancers within our poticy work and matching our capability to respond to the increase in ongoing greater demand across our services. We have now concluded the bulk of our capitaL refurbishment across our retail estate and are focusing on the finaLisation of EPOS rolL This implementation commenced during the year and wilL conclude in the next financialyear, with expectations of improved productivity, increased visibility across retail and to support an upLift in Gift Aided donated stock. We believe that we have sufficient funds balances within our retail improvement programme and EPOS funds to support this. The trustees have therefore approved an increase to the Community Insight and Emotional Support Fund. Designated Funds Increase Community Insight, PoLicy and Emotional Support Fund - to support our commit-ment to the work we are Looking to provide in the community 160,391 Our reserve poLicy 15 set by the trustees based on an assessment of the possible risks that the charity faces in determining the minimum amount of unrestricted reserves to hoLd. They have had to consider the following when setting this: cnoK'us Cancor Care Annual i.: | Ye¢r Ending 31 2025 40. Continuing gLobal trade position and heightened risk of both ongoing and potential confLicts across the world, impacting the volatility of our investments valuation SLOW economic recovery and impact on our funding sources at the same time as seeing an increase in demand for our services and support. The increase in the National Living wage for next year and the significant EmpLoyers NationaL Insurance banding changes and increase in Nl employers percentage charge with potential future years, increases Ongoing delay in legacy settlement due to mix of notified legacies including a propety to manage as well as continued backlogs through probate courts; and Predicting impact on forecast income of the economic climate. The trustees have therefore set the reserves policy to offset these risks at £2.77m for the year-end position. Comparing the unrestricted reserves at £5.32m and deducting the non-convertibLe fixed assets this left reserves of £4.95m which amounted to a surplus of £2.18m which can be deployed in future tinanciaL years. At March 2025, group reserves stood at £7.9m (2023/24.. £8.8ml. This was made up of restricted funds £0.79m (2023/24: £0.7m), designated funds £l.8m (2023/24: £1.9m) and unrestricted reserves of £5.3m (2023/24: £6.Im} at 31st March. 41 Tenovus Cancel Care Annual Repori and Accoutiig l Yeai. Ending 31 Maicl) 2025 Statement ol Trustees. Responsibilxties lor the Financial Statements and CorporfAte Governance The trustees (who are also Directors of Tenovus Cancer Care for the purposes of company Law> are responsibLe for preparing the Trustees, Report (incorporating the Directors, report) and the fi.nancial statements in accordance with applicable law and United Kingdom Accounting Standards, incLuding Financial Reporting Standard102 The Financial Reporting Standard applicabLe in the UK and Republic of Ireland (United Kingdom GeneraLLy Accepted Accounting Practice). Company law requires the trustees to prepare financial statements for each finarbcial year which give a true and fair view of the state of affairs of the charitabLe company and the group and of the income and expenditure of the charitable group for that period. In preparing these financial statements, the trustees are required to: select Suitable accounting policies and then apply them consistentLy observe the methods and principles in the Charities SORP make judgments and accounting estimates that are rea50nabLe and pwdent state whether appLic3bLe UK Accounting Standards have been followed, subjett to any materiaL departures disclosed and explained in the financial statements prepare the financial statement5 on the going concern ba515 unless it is inappropriate to presume that the charitable company wilL continue in business The trustees are responsibLe for maintaining proper accounting records which disclose with reasonable accvracy at any time the financiaL position of the charitable company and enable them to ensure that the financiaL statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregutarities. In so far as the trustees are aware.. there is no relevant audit information of which the charitabLe company's auditors are unaware. the trustees have taken aLL steps that they ought to have taken to make themselves aware of any reLevant audit information and to establish that the auditors are aware of that information. The trustees are responsibLe for the maintenance and integrity of the corporate and tinanciaL information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financiaL statements may differ from Legislation in otherjurisdictions. Auditors A resotution will be proposed to appoint auditors at the forthcoming Annual General Meeting. Signed by order of the Twstees Hazel Sweeney FCA- Company Secretary- Date 23 July 2025 Laiiclbi I rJf£' ￿.. ,11 .41 K',a'. ch 2025 42. Independent Auditors. report to the members ol Tenovus Cancer Care Opinion We have audited the financiaL statements of Tenovus Cancer Care (the 'parent charitable company,) and its subsidiary (the 'group') for the year ended 31 March 2025 which comprise the consolidated Statement of Financial Activities, the consolidated and parent BaLance Sheet, the consolidated Statement of Cash Flows and notes to the financiaL statements, incLuding significant accounting poLicies. The financial reporting framework that has been applied in their preparation is applicabLe law and United Kingdom Accounting Standards, including FinanciaL Reporting Standard102 The Financial Reporting Standard applicabLe in the UK and RepubLic of IreLand (United Kingdom Generally Accepted Accounting Practice). In our opinion the financial statements: give a true and fair view of the state of the group and parent charitable company's affairs as of 31 March 2025, and of the group's incoming resources and application of resources, incLuding its income and expenditure, for the year then ended; have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice", and have been prepared in accordance with the requirements of the Companies Act 2006. Basis for opinion We conducted our audit in accordance with Intemational Standards on Auditing (UK) IISAS IUK)) and appLicable Law. Our responsibiLities under those standards are further described in the Auditor's responsibilities for the audit of the fi'nanciaL statements section of our report. We are independent of the group and parent charitabLe company in accordance with the ethicaL requirements that are reLevant to our audit of the financiaL statements in the UK, including the FRC'S Ethical Standard, and we have fuLfilled our other ethical responsibiLitie5 in accordance with these requirements. We beLieve the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Conclusions rclcTting to going concern In auditing the financial Statements, we have concluded that the trustees, use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any materiaL uncertainties reLating to events or conditions that, individuaLLy or collectively, may cast significant doubt on the group or parent's charitable company's abiLity to continue as a going concern for a period of at Least tweLve months from when the financiaL statements are authorised for issue. Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the reLevant sections of this report. Other informcrtion The other information comprises the information included in the trustees annuaL report, other than the financial statements and our auditor's report thereon. The trustees are responsibLe for the other information contained within the annuaL report. Our opinion on the financiaL statements does not cover the other information and. except to the extent otherwise explicitly stated in our report, we do not express any form of assurance concLusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materiaLly inconsistent with the fi'nanciaL statements or our knowledge obtained in the course of the audit or othemise appears to be materiaLLy misstated. If we identify such materiaL inconsistencies or apparent material misstatements, we are required to deterrnine 43. Tencvus Cance, Cai e Ani)ual Repon and.4ccouni¢ | Year Encjing 31 March 2025 whether this gives rise to a materiaL misstatement in the fi'nanciaL statements themselves. If, based on the work we have performed, we concLude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. Opinions on other matters prescribed by the Companies Act 2006 In our opinion, based on the work undertaken in the course of the audit: the information given in the trustees, report (incorporating the strategic report and directors report} for the financialyear for which the financiaL statements are prepared is consistent with the financiaL statements,. and the strategic report and the directors report included with the trustees report have been prepared in accordance with appLicable legaL requirements. Mcxtters on which we cxre rpquired to report by exception In the light of the knowledge and understanding of the group and parent charitabLe company and its environment obtained in the course of the audit, we have not identified materiaL misstatements in the strategic report and the director5, report included within the trustees report. We have nothing to report in respect of the foLLowing matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion: adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or the parent charitable company's financial statements are not in agreement with the accounting records and returns; or certain disclosures of directors, remuneration specified by Law are not made; or we have not received aLL the information and explanations we require for our audit. Responsibilities of Trustees As expLained more fully in the trustees, responsibiLities statement set out on page 42, the trustees (who are also the directors of the parent charitable company for the purposes of company Law) are responsible for the preparation of the financiaL statements and for being satisfied that they give a true and fair view, and for such internaL controL as the trustees determine is necessary to enabLe the preparation of financiaL statements that are free from materiaL misstatement. whether due to fraud or error. In preparing the financial statement5, the trustees are re5ponsibLe for assessing the groups and parent charitable company s abib.ty to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to Liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so. Auditor's responsibilities for the cxudit of the financial statements Our objectives are to obtain reasonable assurance about whether the financiaL statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high leveL of assurance but it is not a guarantee that an audit conducted in accordance with ISAS (UK) WILI aLways detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they couLd reasonabLy be expected to influence the economic decisions of users taken on the basis of these financial statements. TcnDvU' Cancer Care f4riril' l Rc'porl ,1 , i Accouni: | Year Eiidi4y 31 li 2025 44. Irregularities, including fraud, are instances of non-compliance with Laws and reguLations. We design procedures in line with our responsibiLities, outlined above, to detect materiaL misstatements in respect of irregularities, incLuding fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed beLow: The engagement partner ensured that the engagement team coLLectively had the appropriate competence, capabiLities and skills to identify or recognise non-compliance with appLicable laws and regulations. We obtained understanding of the Legal and regutatory frameworks applicable to the company and the sector in which they operate. We determined that the foLlowing Laws and regulations were most significant: The Companie5 Act 2006, UK corporate taxation laws. employment LegisLation and heaLth and safety LegisLation. We obtained an understanding of how the company is complying with those LegaL and regulatory frameworks by making inquiries to management. We corroborated our inquiries through our review of board papers, minute5 and legal correspondence. We assessed the susceptibility of the company's financial statements to material misstatements, incLuding how fraud might occur. Audit procedures performed by the engagement team included: making enquiries of management as to where they considered there was susceptibility to fraud, their knowLedge of actual, suspected and alleged fraud; identifying and assessing the design effectiveness of controLs management has in place to prevent and detect fraud; understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process; performing anaLytical procedures to identify any unusual or unexpected reLationships; challenging assumptions and judgements made by management in its signifi'cant accounting estimates; identifying and testing journaL entries, in particular any journaL entries posted with unusuaL account combinations,. and assessing the extent of compliance with relevant laws and regulations. There are inherent limitations in our audit procedures described above. The more removed that Laws and regulations are from financial transactions, the Less LikeLy it is that we would become aware of non- compLiance. Auditing standards aLso limit the audit procedures required to identify non-compliance with Laws and reguLations to enquiries of the directors and other management and the inspection of reguLatory and legal correspondence, if any. MateriaL misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deLiberate concealment or collusion. A further description of our re5ponsibilitie5 for the audit of the financial statement5 15 Located on the Financial Reporting Council's website at: vwww.frc.org.uk/auditorsresponsibiLities. This description forms part of our Report of the Auditors. 45. T¢1 IL,oiik Caiiie.. (￿re Aiji'iiiol Repuil aiid 4LCUlJ'.I(s i Eiidii Iq 31 Ma'.cl) 2025 Use of our report This report is made solely to the charitabLe company's members, as a body, in accordance with Chapter 3 of Part16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by Law. we do not accept or assume responsibiLity to anyone other than the charitable company and the charitabLe company's members as a body, for our audit work, for this report or for the pinions we have formed. Stephen John B ckerton FCCA (Senior Statutory Auditor) For and on behalf of Advantage Accountancy and Advisory Limited Chartered Certified Accountants and Statutory Auditors Second FLoor, AvaLon House 5-7 CathedraL Road, Cardiff, CFI19HA len0￿￿) Lancer Larc Annval kleporl aiid Accounis l i'par Endin9 3110,aTch 2025 46. Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 47 Financial Ststements Consolidated Statement of Financial Activities for the year ended 31 March 2025 (in¢orporating income and expenditure account and statement of recognised gains and losses)- Note Unrestricted Funds 2025 Restricted Funds 2025 Total 2025 Total 2024 INCOME & ENDOWMENTS FROM: Donations & Legacies Total Fundraising Income 1,479,182 563.678 2,042,860 3.262.684 1,479,182 563,678 2,042,860 3,262,684 Expenditure Raising funds- donations & legacies Total Fundraising Expenditure (1,262.650> (205) (1,262,855) {1.097,649) (1.262,650) {205) (1,262,855) (1,097,649) Fundraising Contribution Investrnent income Other income Total Contribution from Income & Endowments 216,532 563,473 780.005 2,165,035 145,644 574 362,750 145,644 574 926,223 115,066 14,109 2,294.210 563,473 Retail Operations Trading Income Ratail Operations Trading Expenditure Contribution from Retsil Operations Other Trading Activities Income Other Trading Activities expenditure Contribution from Other Activities Total Contribution from Trading Activities 5,594,669 5,594,669 5,581,918 (5,360,966) (10,203) (5,371,169) (5,142,933) 233,703 (10,203) 223,500 438,985 784,879 262 785,141 677,319 (367.708) (367,708) (303,995) 417,171 262 417,433 373,324 650,874 19,941) 640,933 812,309 Tenovus Cancer Care Annual Reports and Aeeounts Year Ended 31 March 2025 Consolidated Statement of Financial Activities for the year ended 31 March 2025 (incorporating income and expenditure account and statement of recognised gains and losses) continued Net income available for Charilable Activities 1,013.624 553,532 1,567,156 3,106,519 Charitable Expenditure Benefit Advisors Counselling Support Line Mobile Units Sing wilh Us Sup ort Grou Research. Policy & Ins￿ht Community En ement Total Charitable Expenditure Net 9,651,096 (8,792,857) Net gainl(loss) on investments 16 67,689 67,689 400,935 Net (Expenditurey Income Transfer between funds Gainsl (Losses) on disposal of fixed assets Net movement in fvnds Reconciliation of fvnds Funds brought fonmard at 1 April 2024 Total funds carried forward at 31 March 2025 (906,222) (11,429) (917,651) 1,259,174 (80,190) 80,190 13 350 350 6,000 (986.062) 68,761 1917,301) 1,265,174 22 8,089,423 726.569 8,815.992 7.550,818 22 7,103,361 795,330 7,898,691 8.815,992 The deficit for thè year for Companies Acl purposes comprisès Ihe net incomel(expenditure> for the year of £917,651 deficit (202312024.. £1,259,174 surplus), with an additional gain of £350 (202312024: £6,Cx)O gain) on disposal of fixed assets giving a net deficit of £917,3011202312024:£1,265,174 surplus}. There is no tax payable on any of Ihe activities. The notes on pages 5241 form part of these financial statements. Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 MaKh 2025 Balance Sheets as at 31 March 2025 Group Charity 2025 Note 2025 2024 2024 FIXED ASSETS Tangible assets Intangible assets Investments 14 1,132.882 1,161,944 67.690 1.132.882 1.161,944 15 102.056 102.056 67.690 16 5,439.833 4.902.431 6.132.065 5.439.833 6.674.771 4.902,431 6,132,065 6,674,771 CURRENT ASSETS Stock 17 22.367 Debtors 18 780.678 1.287,373 1,614,144 1.830.383 777,886 1.671.899 Cash at bank and in hand 24 1,279,050 1,782,676 2.068.051 3.466,894 2,056.936 3,4¥575 CURRENT UABILrriES Creditors: amounts falling due within one year 19 {802,514} (740.967) (796.399>) (729.478) NET CURRENT ASSETSI{LIABIUTIES) Provisions for liabilities 1,265,537 2.72S927 1,260,537 2,725.097 20 (41,617) {42,000) (41.617) (42,000) TOTAL NET ASSErs 7,898.691 8.815.992 7,893.691 8,815,162 FUNDS Unrestricted Parent charity Subsidiary Company 22 7.098,361 8,088.593 830 7,098.361 8,088.593 22 5.000 Total unrestricted funds 22 7,103,361 8,089.423 7,098,361 8,088,593 Reslricted 22 795,330 726,569 795,330 726,569 7.898.691 8.815.992 7,893,691 8,815,162 The trustees have prepared group accounts in accordance with section 398 of Companies Act 2006 and section 138 of the Charities Act 2011. The financial statements on pages 47-81 were approved by the Board of Directors on 23 July 2025 and were signed on their behalf by Tracey Burke Director Christopher Thomson - Director ,11￿ The notes on pages 52-81 fo￿ part of these financial statements. Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 Consolidated Statement of Cash Flows for the year ended 31 March 2025 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net cash providedl (used in) operating activities (Noted on Page 51) 104,726 181,628 CASH FLOWS FROM INVESTING ACTIVITIES: Interest re￿iVed 45,256 100,388 987,747 350 19,019 96,047 2,496,617 6,000 {215,597) (2,623.370) Dividends re-invested Proceeds from sale of investments Proceeds from sale of fixed assets Purchase of tangible and intangible assets Purchase of investsnents (324,017) (1,477.657) NET CASH PROVIDED BY INVESTING ACTIVITIES {667,933) (221,284) CASH FLOWS FROM FINANCING ACTIVITIES: Net change in cash and short-term deposits (investment assets) 20,197 57,769 NET CASH FLOWS PROVIDED BYI (USED IN) FINANCING ACTIVITIES 20.197 57,769 Change in cash and cash equivalents in the reporting period 543,010 18,113 Cash and cash equivalents atlhe beginning of the reporting period 1.830.383 1.812,270 Cash and cash equivalents at the end of the reporting period (Note 24) 1,287,373 1.830,383 The notes on pages 52-81 form part of these financial statements. Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 51 Consolidated Statement of Cash Flows for the year ended 31 March 2025- continued RECONCILIATION OF NET INCOMEI {EXPENDITURE) TO NET CASH INFLOWI (OUTFLOW) FROM OPEK4TING ACTIVITIES 2025 2024 Net Incomel(expenditure) forlhe reporting period before gains and losses on investments and fixed assets (as per the statement of financial activities) {985,340} 858,239 Depreciationlamortisation of tangible and intangible fixed assets Investment income received (Increaseydecrease in debtors Incr8asel{d8crease) in creditors Increasel{decrease) in provisions (Increaseydecrease in stocks 318,713 (145,644) 833,466 61,547 (383) 22,367 274,818 (115,066) (883,384) 54,540 3.000 (10,519 NET CASH USED IN OPERATING ACTIVITIES (PAGE 50) 104,726 181,628 The notes on pages 52-81 fom part oflhese financial statements. Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 52 Notes to the financial statements for the year ended 31 March 2025 1. Accounting policies Tenovus Cancer Care is a private company limited by guarantee and a registered charity. incorporated in England & Wales. Its registered office is 1 sl Floor Jones Court, Womanby Street, Cardiff CF10 18R. The principal accounting policies, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows: Accounting Convention The accounts have been p￿pared in accordan￿ with the charity's Memorandum and Articles and Association, the Companies Act 2006 and "Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). {from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102. The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £. We report retail and fundraising contributions separalely on the fa￿ of the consolidated Statement of Financial Activities (SOFA) to assist in the understsnding of the charity result and to highlight the perforrnan￿ of our retail operation. The accounts have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. Going Concern The trustees have reviewed Tenovus Cancer Care and Tenovus Trading Limited's financial position considering the impact of future activities to ensure it is appropriate to produ￿ the accounts on a going cOn￿M basis. There are no material un￿rtaIntieS aboLrt the group's ability to continue. Basis of Consolidation The consolidated financial statements of the Group incorporate the finanGial statements of Tenovus Cancer Care and its subsidiary und8rtaking, which were made up to 31 March 2025. No separate cornpany Statement of Financial Activities (SOFA) has been prepared for the charity as permitted by section 408 of the Companies Act 2006 and paragraph 24.37 of the SORP. Cash Flow Statement The charity prepares a consolidated cash flow statement and the consolidated accounts, in which the charity's results are included and are available to the public. It has therefore taken advantsge of the exemption conferred by FRS 102 Section 1 not to prepare a separate cash flow statement. Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 Notes to the financial ststements for the year ended 31 March 2025 - continued Incoming Resources Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that income will be re￿ived, and the amount can be measured reliably. Donations and Legacies Legacies - entitlement is taken as the earlier of the date on which either: the charity is aware that probale has been granted and the executor has confimied that a distribution will be made or when a distribution is received from the estate. Receipt of a legacy is only considered probable when the amount can be measured reliably, and the charty has been notified of the executor's intention to make a distribution. Where legacies have been notified lo charity or the charity is aware of the granting probate and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed rf material. Donations categories accounted for on a re￿iVed basis are noted as: Direct giving- cash donations and regular gifts • Major donors - major gifts and income from partnerships. • Volunteer fundraising - income from Friends of Tenovus Cancer Care and local committees of the groups. Donations categories accounted for on an accruals basis are noted as.. • Lottery income • Gift Aid Events- voluntary income arising from major events, principalty sponsorship, is recognised in the period in which the event takes place. Events registration fees are also recognised when the event takes pla￿. Any fees re￿iVed in advance are deferred until the event takes pla￿. Income from charitable activities Grants - related to perfomiance and specific deliverables - are accounted for as the charity 8ams the right to consideration by its performan￿. Where income is received in advance of perfomiance its recognition is deferred until the criteria for income recognition have been met. Where entitlement occurs before the income is re￿IVed the income is accrued. Non-performance related grants are recognised on receipt and any unspent funds are carried forward in restricted reserves. Trading activities Retsil - income is accounled for when the sale takes place. Mobile Support Unit - income is recognised in the month the unit is rented. Sales of merchandise are accounted for when the transaction occurs. Tenovu5 Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 Notes to the financial ststements for the year ended 31 March 2025- continued Investment Income & Other Income Investment income is included when receipt is probable. and the amount receivable can be measured reliably. Royalties received from funded research are recognised on receipt. Resources Expended Expenditure is rewgnised when a liability is incurred or from a legal or constructive obligation to transfer economic benefrts has arisen. This is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to that category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. Contractual arrangements and performance-related grants are recognised as goods or services supplied. For research grants, the charity recognises grant payments when a constructive obligation is met. paymenl is probable, it can be measured reliably, and there are no conditions attached to its payment that limit its recognition. Expenditure in raising funds are those costs incurred in attracting volunlary income and those incurred in trading activities that raise funds and include irrecoverable VAT. Charitable activities include expenditure associated with educational programmes and include both the direct costs and support costs relating to those activities. Support costs include general management. budgeting and accounting, payroll administration, human resources, infomiation technology, facilities and estates, general administration and health and safety and are allocated across charitable and fundraising activities under the following categories: Financial Management, People and Development, Informalion Systems. Facilities and Estates. These costs have been allocated to activity cost categories on a basis consistent with the use of resources, e.g. allocating staff costs by the time spent and other costs by usage. Donated Goods and Services Donated professional services and donated facilities are recognised as income when the charity has control over the item. any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), general volunteer time is not recognised. On receipt. donated professional seNices and donaled facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain se￿I￿S or facilities of equivalent e(x)nomic benefil on the open market, a corresponding amount is then recogni5ed in expenditure in the period of receipt. Tax Tenovus Cancer Care is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Acl 2010 and therefore it meets Ihe definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 Corporation Tax Act 2010 or Section 256 of the Taxation of Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 Mareh 2025 55 Notes to the financial statements for the year ended 31 March 2025 - continued Chargeable Gains Act 1992, lo the extent that such income or gains are applied exclusively to charitable purposes. Profit from the subsidiaries is gifl aided to Tenovus Cancer Care. Employee Benefits The cost of any unused holiday entiuement is recognised in the period in which the empk)yees' seniices are received. Tennination benefrts are recognised immediately as an expense when the charity is demonstrably committed to terminating the employment of an employee or providing termination benefits. Fund Accounting The charity has various types of funds for which it is responsible, and which require separate disclosure. These are as follows: Restricted funds - these funds are restricted by the donor or appeal for specific purposes. Restricted funds for capital spend are expended over Ihe life of the asset. Funds restricted by the donor for revenue spend are held in restricted reserves and funds are matched against expenditure as appropriate. Designated funds - these are unrestricted funds that have been set aside at Ihe discretion of the Trustees for particular purposes. INhere capital expenditure has been incurred this is expended over the life of the asset. Unrestricted funds - these funds compromise accumulated surpluses and deficits on general funds that are expendable at the discretion of Ihe Trustees in furtheran￿ of the objecls of Ihe charity and that have not been designated for other purposes. Fixed Assets Tangible fixed assets costing more than £1 ,000 are capitalised and induded at cost together with any incidental costs of acquisilion. Depreciation is calculated to write off the cost of tangible fixed assets on a straight-line basis beginning in month post actual usage over the expected useful economic lives of the assets concerned. The principle annual rates used for this purpose are. Leasehold improvements to shops 5 years, 10 years or remaining lease tenn Motor Vehicles 25 % 33.330/0 Fixtures and Fittings and IT equipment Mobile Support Units and Tractors 5-10'/o Short leasehold premises over the period of the lease Tenovus Cancer Ca Annual Reports and Accounts Year Ended 31 March 2025 Notes to the financial statements for the year ended 31 March 2025 - continued Impairment of fixed assets Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time, value of money, and the risks specific to Ihe asset for which the estirnates of future cash flows have not been adjusted. If the recoverable amount of an asset is estimated to be less than its carrying amount, the carying amount of the asset is reduced to its recoverable amount. An impairment loss is recognised immediatety in incomel (expenditure) for the year, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease. Recognised impainnenl losses are reversed if. and only if, the reasons for the Impai￿nent loss have ceased to apply. Where an impaimient loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been detemiined had no impairment loss been recognised for the asset in prior years. A reversal of an impaiment loss is recognised immediately, unless the relevant asset is carried in at a revalued amount, in which case the reversal of the impairment loss is treated as a valuation increase. Intsngible Assets Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cosl less accumulated amortisation and accumulated impairment losses. Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributsble to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal righls; and the intsngible asset is separable from the entity. Amortisation is recognised to write off the cost or valuation of assets less their residual values over their useful lives applying the following rates- Software Using a range from 200/. - 500A depending on asset lrfe. Stocks Stocks comprise of merchandise purchased for resale and consumables. These are stated at the lower of cost and net realisable value, with a write down provision deducted for slow moving stocks. Donated goods for sale in the Groups, charity shops are not valued. Operating Leases Rental costs under operating leases are charged on a straight-line basis to the SOFA over the lease tem. Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 Notes to the financial statements for the year ended 31 March 2025- continued Invesljnents Fixed asset investments in quoted shares. traded bonds and similar investments are valued initially at cost and subsequently at fair value (their market value) at the year end. The same treatment is applied to unlisted investments unless fair value cannot be measured reliably in which case it is measured at cost less impairment. Inveslments in subsidiaries are included within the financial statements at cost. A subsidiary is an entity controlled by the charity. Control is the power to govem the financial and operating policies of the entity so as to obtain benefits from its activities. Investrnents held for resale or pending their sale and cash and cash equivalents with a maturity date of less than one year are Ireated as current asset investmenls. Current Asset Investments The charity has investments which it holds for resale or pending their sale and cash and cash equivalents with a maturity date less than one year. These indude cash on deposit and cash equivalents with a maturity date of less than one year held for investment purposes rather than to meet short-temi cash commitrnents as they fall due. They are valued at fair value except where they qualify as basic financial instruments. Cash at Bank and in Hand Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity from the date of acquisition or opening of the deposit or similar account. Financial Instruments The charity has elected to apply the provisions of Section 11 '8asic Financial Instruments, and Section 12 'Other Financial Instruments Issues. of FRS 102 to all of its financial instruments. Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the assets and settle the liability simultaneously. Baslc financial assets Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequendy carried at amortised cosl using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the fvture re￿iptS discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised. Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 Notes to the financial statements for the year ended 31 March 2025 - continued Impairment of financial assets Financial assets, olher than those held at fair value through income and expenditure, are assessed for indicators of impairment at each reporting date. Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flow has been affected. If an asset is impaired, the impainnent loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in net incom81(expenditure} for the year. If there is a decrease in the impaimient loss arising from an event occurring after the impainnent was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed vthat the carrying amount would have been. had the impairment not previously been recognised. The impairment reversal is recognised in. net iD.comel(expenditure) for the year. De.recognition of financial assets Financial assets are de-recognised only when the contractual rights to the cash flows from the asset expire or are settled. or when the charity transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party. Basic financial liabilities Basic financial liabilities. including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing Iransaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised. Debl instwments are subsequently carried at arnortised cost, using the effective interest rate method. Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method. De.recognltion of flnancial liabilities Financial liabilities are de-recognised when the charity's contractual obligations expire or are discharged or cancelled. Pension Costs The charity contributes to a voluntsry defined contribulion pension scheme for the majority of permanent employees and provides benefits based on contributions made. The assets of the scheme are held in trustee-adrninistered funds completely independent of the charity's finances. The charity has no legal or constructive obligation to pay further contributions in the event that these plans do not hold sufficient assets to provide future benefrts. Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 59 Notes to the financial statements for the year ended 31 March 2025- continued Auto-enrolment for the charity commenced in April 2014 and the charity is complying with its obligations. Foreign Exchange Policy Transactions in fO￿Ign currency are recorded at the rate of exthange prevailing at the time of the transaction. Foreign currency balances are translated into sterling at the exchange rates prevailing at the balance sheet date. Any resulling gains or losses on exchange are included in the SOFA. Critical Accounting Estlmates and Judgements In the application of the charty's accounting policies. the trustees are required to make judgements. estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estirnales are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods. 2. Donations and Legacies Unrestrlctsd Reslricted 2025 2024 Donations & Grfis Legacies Trusts & Grants Donated Goods & Services 522.068 851.072 7.283 529,351 851,072 556,395 106,042 2,042,860 577.779 2.365.992 192,468 126.445 3,262,684 556,395 106.042 1,479,182 563,678 3. Retail Operations and OtherTrading Activities 2025 2024 Retail Operations Shop income New Goods in Trading Subsidiary (3a) 5.484.535 110.134 5.594,669 5.480.418 101.500 5,581,918 Other Trading activities Mobile Unit Income in Trading Subsidiary (3a) Contribution to Mobile Units within Charity Events Lottery 203,071 152,051 221,207 208,812 785,141 6,379,810 103.358 194,518 189,053 190,390 677,319 6,259,237 Included in event income is £262 of restricted income Tenovus Cancer Caro Annual Rèports and Aeeounts Year Ended 31 March 2025 Notes to the financial statements for the year ended 31 March 2025- continued 3a. Trading Operations in Subsidiary The charity has a trading subsidiary, Tenovus Trading Limited, company number 01157332. a company limited by guarantee which is incorporated in the UK. The subsidiary sells greeting cards, calendars and other promotional goods, and covenants all its taxable profits to Tenovus Cancer Care. The subsidiary also rents mobile units from the charity for its own use. A summary of its trading r8sults follows. 2025 2024 INCOME & EXPENDITURE ACCOUNT Tumover New Goods Mobile Unit 110,134 203,071 313,205 101,500 103,358 204,858 Net operating expenses new goods Net operating expenses mobile unit (146,606) (114,372) (125.162) (83,717) Operating surplusl(deficit) 52,227 (4,021) Prior year funds Amount covenanted to Tenovus Cancer Care 48.057 Retained in subsidiary 4,170 A summary of its aggregate assets, liabilities and funds is as follovrfs: Assets 40,661 124.136 Liabilities (35,661) (123,306) Funds 5,000 830 The mobile unit usage is charged at a slandard daily rate through to Tenovus Trading Limited for the costs incurred. 4. Investment Income Unrestricted Restricted 2025 2024 Dividend income Interest receivable 100,388 45,256 100,388 45,256 96,047 19,019 145,644 145,644 115,066 Tenovus Cancer Caré Annual Reports and Accounts Year Ended 31 March 2025 61 Notes to the financial statements for the year ended 31 March 2025- continued 5. Other Income Unrnstrlcted Restricted 2025 2024 Other income 574 574 14,109 574 574 14,109 6. Expenditure for Raising Donations Legacies and Other Unrestrlcted Restrlcted 2025 2024 Donations & Gifts (6a} Donated goods and seriices (6b) Legacies and Trusts Investment Managernent Costs 907.477 106,042 218.456 30.675 205 907,682 106,042 218,456 30,675 745,494 126.445 198,647 27.063 1,262.650 205 1,262,855 1.097,649 6a. Donations and Gifts Unrestrlcted Restrlcted 2025 2024 Staff & other related costs Other costs Support costs 370.462 243,661 293,354 907.477 370,462 243,866 293.354 907,682 293.695 138,796 313,003 745,494 205 205 6b. Donated Goods & Services Unrestricted Restricted 2025 2024 Publicty Mobile Support Unit equipment & services Fundraising 93.972 93.972 95.465 20,000 12,070 106,042 12,070 106,042 10,980 126,455 Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 Notes to the financial statements for the year ended 31 March 2025- continued 7. Retail and OtherTrading Activities Retail Operations 2025 2024 Retail shops cosls (7a) Cost of sales on new goods {subsidiary) (note 3a) 5.224,563 146,606 5,371,169 5,017,771 125.162 5,142,933 other Trading Activities Event costs Lottery Mobile Units Costs (subsidiary) (nole 3a) 180.073 73.263 114,372 367,708 5.738,877 169,479 50.799 83.717 303,995 5.446.928 Included within the retail shops costs for 2024-2025 is £10,203 of restricted expenditure (202312024) £4,956. Unrestricted Restrided Funds Funds 2025 2024 7a. Retail Shop Costs staff & other related costs Rent, rates & insuran Other costs utilities Repairs & renewals DepreciationlAmortisation Support costs 2,599,983 979,301 560,707 329,022 118,710 92,355 534,282 5,214,360 2,599,983 979,301 560.707 329,022 119.854 101,414 534,282 5,224,563 2.340,431 980,248 547,061 365,003 167,123 51,548 566,357 5,017,771 1,144 9,059 10,203 8. Cost of Charitable Actlvltles Unrestricted Restricted Funds Funds 2025 2024 8a. Benefit Advisors staff & other related costs Direct overheads Support costs (9) 126,910 18,125 119,205 264,240 84,811 1,654 211,721 19,779 120,199 351,699 149,737 10,714 147,997 308.448 87,459 Unrestricted Restricted Funds Funds 2025 2024 8b. Counselling Staff & other related ojsts Direct overheads Support costs (9) 54,619 15,300 136,039 205,958 178,284 8,182 232,903 23,482 136,039 392,424 246,931 19.573 164,493 430,997 186,466 Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 63 Notes to the financial ststements for the year ended 31 March 2025- continued Unrestricted Restricted Funds Funds 2025 2024 8c. Support Line Staff & other related costs Direct ovetheads Support costs (9) 148,772 15,811 95,041 259,624 30,808 179,580 15,811 95,041 290,432 153,678 12,206 115,005 280,889 30,808 Unrestricted Restricted Funds Funds 2025 2024 8d. Mobile Support Units Staff & other related costs Direct overheads Support costs (9) 189,865 102,559 122.994 415,418 30,295 122.000 220,160 224,559 122,994 567,713 195,704 240,911 115,005 551,620 152.295 8e. Sing with Us Support Groups Unrestrictsd Restrlcted Funds Funds 2025 2024 Staff costs Direct overhead costs Support costs (9) 149,943 106.694 108,397 365,034 3,233 4,675 153,176 111,369 108,397 372,942 161,882 92,421 147,997 402,300 7,908 8f. Research. Policy & Insight Unrestrictsd Restricted Funds Funds 2025 2024 Research grants Staff costs Direct overhead costs Support costs (9) {44,440) 114.146 48,389 82,013 152,366 127,075 87,432 152,366 139,345 87,432 12,270 366,873 12,270 379,143 200,108 8g. Community Engagement Unrestricted Restricted Funds Funds 2025 2024 Staff costs Direct overhead costs Support costs {9) 47.599 10,287 52.502 80.429 2,524 4.802 128,028 12,811 57,304 66,442 4.676 110,388 87,755 198,143 73,918 Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 Notes to the financial ststements for the year ended 31 March 2025 - continued 9. Support Costs Total 2024 Other overheads Staff costs Total 2025 Retail & Subsidiaries Cosls of Raising Funds Benefit Advisors Counselling Support Line Mobile Support Units Sing with Us Support Groups Research, Policy & Insight Community Engagement 209,578 112.215 43,083 48.760 34,065 44,084 38,853 31,338 20,539 582,515 375,140 200.861 77,116 87.279 60.976 78,910 69,544 56,094 36.765 1,042,685 584,718 313.076 120,199 136.039 95.041 122,994 108,397 87,432 57.304 1,625,200 615,237 328,986 147,997 164,493 115,005 115.005 147,997 82.013 4,676 1,721,409 10. Stsff Costs And Trustees, Remuneration 2025 2024 Wages & salaries Redundancy & termination payments Social security costs Other pension costs (note 25) 5,042,408 4,486,613 414.311 221.107 5,677,826 356.067 213,227 5,055,907 The number of higher paid employees was as follows: 2025 Number 2024 Number £60,001- £70,000 £70.001- £80.000 £110.001- £120,000 £120.001- £130.000 The number of higher paid employees for whom retirement benefits are accwing: 2025 Number 2024 Number £60.001- £70.000 £70.001- £80.000 £110,001- £120,000 £120,001- £130,000 Tenovus Cancèr Caré Annual Reports and Accounts Year Ended 31 March 2025 65 Notes to the financial statements for the year ended 31 March 2025- continued Pension contributions for higher paid employees are as follows: 2025 2024 £60,001- £70,000 £70,001- £80,000 £110,001-£120.000 £120,001- £130,000 10,573 9,588 20,016 8,351 8,453 No trustee has received any remuneration from the Group during the year (2023124: £nil). During the year 1 trustee received reimbursement of travel & subsistence of £310 (2023124: £163 (1)). Key Management Personnel The key management personnel of the parent charity comprise the Leadership Team listed on page 35. Total remuneration of Key Management Personnel in the year was £497.899 (2023124: £485,381). 11. Staff Numbers The average number of slaff employed during the year was 226 {2023124: 218). The average number of full equivalent (FTE) staff employed during the year is shown below. 2025 Number 2024 Number Average number of employees Ifull time equivalent) 176 179 Benefit Advisors - costs allocaled to statement of financial activities - benefit advisor costs Support Llne- costs allocated to statement of financlal activitles- support line costs Counselling - costs allocated to statement of financial activities- counselling cosls Mobile Units - costs allocated to statement of financial activities- mobilè unit cost Sing with Us Support Groups- costs allocated to statement of financial activities - Sing with Us support groups Research. Policy & Insight- allocated to statement of financial activities- research. policy & insight costs Community Engagement- allocated to statemenl of financial activities- community engagement Costs Income Generation Department- allocated to statement of financial activities - cost of raising funds Head Office - allocated to statement of financial activities -support costs Marketing & Communication- allocated to statement of financial activities support cosls Shops- allocated to the statement of financial activilies- retail costs 12 14 102 176 101 179 Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 Notes to the financial statements for the year ended 31 March 2025- continued 12. Net Incomel (Expenditure) for the Year As pemiitted by Section 230 of the Companies Act 2006, Ihe parent company's income and expenditure account has not been included in these financial statements. The incoming resources forthe year are made up as follows: 2025 2024 Income generated by parent charitable company 8,255,684 9,466,238 Expenditure by parent charitable company (9,293,251) (8,583,978) Investments gainsl(losses) 68,039 406,935 Share of incoming resources generated by subsidiary in year and covenanted to this company (Note 3a) 48,057 Loss generated by subsidiary in year (4,021) (921,471) 1,265,174 13. Net Incoming Resources Net incoming resources for the year is stated after charging: 2025 2024 Gift Aid income Depreciation of tsngibles Amortisation of Intsngibles Auditors. remuneration- audit fee Land and buildings operating lease costs other operating lease ￿$ts Gainl(loss) on disposal of tangible fixed assets 355,080 286,621 32,092 22,360 934,504 91,834 350 352,742 238.048 36,770 22.250 952,988 53.544 6.000 111 111111 111 1111 1111111 1111111 111 1111 1111 Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 Notes to the financial statements for the year ended 31 March 2025 - continued 15. Intangible Fixed Assets Charily & Group Software TOTAL Acqulsition Cost At 1 April 2024 Addilions Disposals 235,668 66,458 235,668 66,458 At 31 March 2025 302,126 302,126 Amortlsatlon At 1 April 2024 Charge for the year Eliminated on disposal 167,978 32,092 167,978 32,092 At 31 March 2025 200,070 200,070 Net Book Value at 31 March 2025 102,056 102,056 Net Book Value at 31 March 2024 67,690 67.690 16. Fixed Asset Investments Group & Charity 2025 2024 Fair value at 1 April 2024 Less: disposals at opening fair value Add: acquisitions at cost 4,902,431 (984.284> 1,477,657 4,432,513 (2,418,488) 2.623.370 Net unrealised investment gainsl(losses) Increasel(decrease) in cash as held as part of investment portfolio 64,226 (20,197) 322.805 (57.769) Fair value al 31 March 2025 131 March 2024 5,439,833 4,902,431 Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 Notes to the financial ststements for the year ended 31 March 2025- continued Split by 2025 2024 Fixed Asset Investments Represented by: Corporate bond and bond funds Equities other Investments Cash & short-T8￿￿ bonds held as part of investment portfolio 822,990 3,603,071 815,771 198,001 868,499 3,094,711 842,283 96,938 Fair value at 31 March 2025 131 March 2024 5,439.833 4,902,431 Cost at 31 March 2025131 March 24 4,943,215 4,495,937 In the year to 31 March 2025 the charity had realised gains of £3,463 (2023124: £78,130 gain), unrealised gains of £64,226 {2023124 £322,805 gain). At 31 March 2025 3 (2023124: 4) individual holding of investments represent8d more than 50/0 of the total carrying value of investments. 16a. Investment in Subsidiary The company's investments at the balance sheet date include the following: Tenovus Tradln Llmlted Country of Incorporation Type Holding Principal Activity England & Wales Company Limited by Guarantee Tenovus Cancer Care holds the guarantee Trade Activities to support charity Tenovus Cancer Caro Annual Rèports and Accounts Year Ended 31 March 2025 70 Notes to the financial statements for the year ended 31 March 2025 - continued 17. Stocks Group 2025 Charfty 2025 2024 2024 Greeting cards & merchandise 22,367 22,637 18. Debtors Group 2025 Charity 2025 2024 2024 Amounts falling due within one year: Trade debtors Amount due from subsidiaries Other debtors Prepayments Accrued Income 70,235 82,950 40,762 33,715 29.546 68,654 298,039 340,885 777,886 111,817 123,739 336.212 1.066.416 1,617,899 68,654 300,904 340,885 780,678 123,739 341,039 1,066,416 1,614,144 19. Creditors Group 2025 Charity 2025 2024 2024 Amounts falling due within one year: Trade creditors Accruals Deferred In￿Me {19a) Other creditors 307,923 218,710 149,028 126,853 271,789 249,701 102.051 117,426 305,751 214,767 149,028 126,853 268.796 241.205 102,051 117.426 802,514 740,967 796,399 729,478 Tonovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 71 Notes to the financial statements for the year ended 31 March 2025 - continued 19. Creditors (continued) Group 2025 Charity 2025 19a Deferred Income 2024 2024 Opening Balan 102,051 136,092 102,051 136,092 Received In the year 314.376 256.092 314.376 256.092 Released in the year (267,399) {290,133) (267,399) (290,133) Closing Balan 149,028 102,051 149,028 102,051 20 Provisions for Liabilities Group 2025 Charity 2025 2024 2024 Legal Fee Provision Dilapidations Proviston 19.617 22.000 41,617 20.000 22,000 42,000 19.617 22.000 41,617 20.000 22,000 42,000 Legal Fees 2025 Dilapidalions 20a Provisions for Llabilities- Group & Charlty 2024 2025 2024 Opening Balan 20,000 25,000 22,000 14000 Provided in Ihe year 8,000 Released in the year (383) (5.C(Q) Closing Balance 19,617 20,000 22,000 22,000 The legal fee provision represents future legal costs related to the administration of complex legacy estales. We expect these payments to be made within the next 1-2 years. The dilapidation provision represents future costs for shops that have closed. These payments are expected to be made with the next year but are subject to negotiations with landlords. Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 72 Notes to the financial statements for the year ended 31 March 2025 - continued 21. Financial Instruments Group 2025 Charity 2025 2024 2024 Flnancial assets measured at fair value Invesknents 5,439.833 5,439.833 4,902,431 4,902,431 5,439,833 4,902,431 5,439,833 4.902.431 Financial assets measured at amortised cost Trade debtors Other debtor transactions Cash 70.235 409.539 1,287,373 1.767.147 82,950 1,190,155 1.830,383 3,103,488 40,762 33,715 443,255 1,301,972 1,279,050 1,782,676 1,763,067 3,118,363 Financial liabilities measured at amortised cost Trade creditors Other creditortiansactions 307.923 345.563 653.486 271,789 367,127 638,916 305,751 345.790 651,541 268,796 358,631 627,427 Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 73 Notes to the financial statements for the year ended 31 March 2025- continued 22. Funds Balance at 1 April 2024 Income Expenditure Investment gainsl losses Transfers between Funds Balance at 31 March 2025 Unrestricted General Fund Designated Funds Development of Sustainable Income Streams Fund Office Move Fund Community Insight. Policy and Emotional support 6,116,299 7.691,744 (8,427,780) 68,039 (123,321 > 5.324,981 5,467 (1,727) 3,740 33,102 350,000 (7,648) (46.232) 25,454 464,159 160.391 Increased Digitalisation in Charity Fund 391.700 (116,907) 274,793 Retsil Improvement Programme 818.032 (114,338) 703,694 EPOS Implementation Fund Less Survivable Cancers Fund End of Life Fund 200.000 104,790 {3,250) 101.540 69,203 (69.203) Total Unrestricted B,088,593 7,691,744 (8,717,882) 68,039 {32,133) 7,098,361 Restricted Equipment Fund Mobile Units Capital Fund Mobile Units Running Costs Fund 14,453 (1,456) 12,997 456.137 (99,188) 356,949 47,073 7.793 (52,793) 2.073 Policy & Insight Fund Retail Fund Support SerVI￿s Fund Support Groups Fund Volunteering Fund Fundraising Fund Total Restricted 31,047 23.457 {12,270) (9,059) 18,777 63,821 10,274 39,149 186.602 780 11,250 477,379 12,809 11,250 205 {362,385) (7,909) (30,104) {205) (575,369) 33.437 335,033 5.680 7,604 726,569 563,940 80,190 795,330 Total Charity 8,815,162 8.255,684 (9,293,251) 68.039 48.057 7,893,691 Total Subsldlary (3a) | 830 313,205 {260,978) {48,057) 5.000 Total Group 8,815,992 8.568.889 (9,554,229) 68,039 7,898,691 Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 74 Notes to the financial ststements for the year ended 31 March 2025 - continued 22. Funds (Continued) The group balance sheet also includes non-charitable trading funds of £5,000 (202312024: £830) held in the subsidiary undertaking Tenovus Trading Limited on behalf of Tenovus Cancer Care. Designated Funds The Development of Sustainable Income Streams Fund represents an amount used to develop and maintain sustainable income streams within Ihe charity. The remainder of the fund will be utilised to develop our online trading offering. The Office Move Fund represents funds set aside to cover the charity's move to a pennanent head office premises at Jones Court with reduction in fund matched against capital spend with ongoing amortisation of equipment charged against the fund. The Community Insight Policy and Emotional Support Fund will be used to gather local insight within targeted communities, provide the voice for change and give further support where critical indicators are noted now the development of our work in this area is in pla￿. The Digitalisation across the Charity Fund has supported the IT infrastructure and hardware refresh to underpin the roll out of improved digital solutions across the tharity for income generation and support services. The remainder wlll now be spent on roll out of new software programmes which will assist in the efficienl running of the charity. EPOS Implementation Fund has now been identified to specifically cover the costs of implementing the new electronic point of sale digital system across our retsil portfolio and the project costs thal are associated with this. The Retail Improv8ment Programme Fund continues to be used across the retail ne￿Ork lo respond to innovative ways of shopping whilst upgrading and investing in the traditional shop set up. The Less Survivable can￿rS Fund has been set aside to underpin working in conjunction with partner organisations whose aim It Is to Improve outcomes from these particular cancers with a focus on Upper Gi cancers over the next 12-18 months now with the aim of targeting our existing services to support this group in addition to lung can￿r screening. The End-oflife Benefits Fund was being used to meet the increasing challenges of accessing benefits providing additional adviser support whilst the economic climate persists, together with the challenges around delayed diagnoses as a result of the pandemic. Tonovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 75 Notes to the financial statements for the year ended 31 March 2025- continued 22. Funds (continued) Restricted Funds The Equipment Fund represents a grant for the purchase of medical equipment and water heaters from the Screwfix Foundation and a legacy gifL The Mobile Support Units Capital Funds have been spent across units on a restricted basis by unit as follows: Mobile Support Unit 1- Capitsl redesign represents funding from major donors and trusts to allow full disabled access to the unit. Mobile Support Unit 3- represents funding applied on the capital build from the Simon Gibson Charitable Trust and the James Tudor Foundation The Mobile Support Units Running Costs funds represents funding applied against the ongoing running costs of the units funded by Walk the Walk, The Garfield Weston Foundation, Bridgend Friends of Tenovus Group, Simon Gibson Charitable Trust and some individual donations. The Policy & Insight Fund represents grant funding from an anonymous donor to help improve outcomes for women with gynecological cancer. The Retail Fund represents grant funding from Denbighshire County Council and Ceredigion Cynnal y Cardi UKSPF to be used on capital works on shop premises. The Support Services Fund relates to funding received for support line, advocacy, benefits advi￿, counselling funded by Moondance Foundation, National Lottery Awards for All, The Hodge Foundation, The Shaw Trust, St James Place, Scottish Power Foundation and Rockwool UK. The Support Groups fund represents funding re￿iVed for use on specific support groups such as Sing with Us, including, Conwy Town Council, Co-op Local Community Fund, Powys Church in Wales Grdnt, Groundwork UK, Rhyl Flats offsho￿ WF Community Fund and Millennium Stadium Charitable Trust The Volunteering Fund represents fvnding from the WCVA to be used to fund developing volunteering opportunities. The Fundraising Fund represents donations specifically allocated to fundraising expenditure. Transfers Transfers are made to cover depreciation that is charged on assets bought with restricted funds to refled the capital element. Transfers are also made to cover spend where Tenovus Cancer Care is match funding the project. Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 76 Notes to the financlal statements for the year ended 31 March 2025 - continued 22. Funds - Comparative Reserves Balance at 1 April 2023 Income Expendllure Investment gainsl losses Transfers between Funds Balance at 31 March 2024 Unrestricted General Fund Designated Funds Development of Sustainable Income Streams Fund Office Move Fund Community Insight, Policy and Emotional support 5.384,887 9.254,073 {7,870.979) 406,935 {1,058,617) 6.116,299 52,462 (2,123) (44,872) 5,467 57.864 200,000 (7.657) (17,105) 150,000 33,102 350,000 Increased Digitalisation in Charity Fund 189.811 (148,111) 350,000 391,700 Retail Improvement Programme 402.729 (34,697) 450,000 818,032 EPOS Implementation Fund Less Survivable Cancers Fund End of Life Fund 200,000 200,000 113.320 (8,530) 104,790 81.369 {12,166) 69,203 Total Unrestricted 6,482,442 9,254,073 (8,084,263) 406,935 29,406 8,088,593 Restricted Equipment Fund Mobile Units Capital Fund Mobile Units Running Costs Fund 14.765 {312) 14,453 555.327 {99,190) 456,137 47.073 64.526 {64,526) 47,073 Research Fund Retail Fund Support servI￿s Fund Support Groups Fund Volunteering Fund Total Restricted 26,474 15,230 19,220 (45,694) (4.956) 10,274 396,532 8,124 95,389 1.780 11.250 192.165 (321,607) (9.124) 16.288 186,602 780 11,250 726.569 1,063,525 {499,715) (29,4(ffj) Total Charity 7,545,967 9,446,238 (8,583,978) 406,935 8,815,162 Total Subsidlary {3a) 851 204,858 {208,879) 830 Total Group 7,550,818 9,651,096 (8,792,857) 406,935 8,815,992 Tenovus Cancer Care Annual Reports and Accounts Year Endad 31 March 2025 77 Notes to the financial statements for the year ended 31 March 2025 - continued 23. Analysis Of Fund Balances Between The Net Assets General Funds Deslgnated Funds Restricted Funds Totsl 31 March 2025 Charity Fixedl Intangible assets 381,009 430.888 423,041 1.234,938 Investments 4.768,587 671.246 5,439,833 Net assetsl (liabilities) 175,385 671.246 372.289 1.218,920 Total 5.324,981 1.773.380 795,330 7,893,691 Group Fixedl Intangible assets 381,009 430,888 423,041 1,234.938 Investments 4.768.587 671.246 5,439.833 Net current assetsl (liabilities) 180,385 671,246 372.289 1,223.920 Total 5,329.981 1,773,380 795,330 7,898,691 Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 78 Notes to the financial statements for the year ended 31 March 2025 - continued 23. Analysis Of Fund Balance5 Between The Net Assets continued- Gomparative note General Funds Designated Funds Restrlcted Funds Total 31 March 2024 Charity Fixedl Intangible assets 498,450 265.536 465,648 1,229.634 Investments 4,902,431 4,902,431 Net assetsl labilities 715,418 1,706,758 260,921 2,683,097 Total 6.116,299 1,972,294 726,569 8,815.162 Group Fixedl Intangible assets 498,450 265,536 465,648 1,229,634 Investrnents 4,902,431 4,902,431 Net current assetsl (liabilities) 716,248 1,706,758 260,921 2.683.097 Total 6,117,129 1,972.294 726.569 8,815,992 24. Analysis of Net Funds April 2024 Cash flows 31 March 2025 Net cash analysed In the balance sheet Cash at bank and in hand 1.830.383 (543.010) 1,287.373 Net funds 1,830,383 {543,010} 1,287,373 25. Pension Costs The pension cost represents contributions paid by the charity to the Tenovus Cancer Care Group Personal Pension Plan. a defined contribution scheme. During the year membership of the Pension Plan was offered to all the charity's employees subject to certain restrictions. The charity's contribution amounted to £221,107 (2023124: £213,227). The cDntribution rates ranged between 2 % and 70/0 {2022123: 2 % and 7 % ). At the year- end there was £31,595 outstanding to be paid across to the scheme in relation to current month's pay (2023124.. £28,860). Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 79 Notes to the financial statements for the year ended 31 March 2025 - continued 26. Company Limited by Guarantee The company is limited by guarantee whereby the liabllity of each member is limited to £1. As at 31 March 2025 there were 9 members. 27. Related Party Transactions During the year Tenovus Cancer Care acted as an agent and collected monies totalling £91,193 (2023124: £93,559) on behalf of its wholly owned trading subsidiary Tenovus Trading Limited. The charity also recharged costs totalling £114,372 (2023124.. £83,717) and overheads lo Tenovus Trading totslling £46.447 (2023124: £48.880). At the year end the Tenovus Cancer Care was owed is £29,546 (2023124: £111,817) from T8novus Trading Limited. During the year the charity received donations totalling £80 (2023124: £774) from trustees. These donations were received without any conditions. 28. Financial Commitments At 31 March 2025 the charity had annual commitments under nOn-Can￿lIable operating leases as follows: Other Land & Buildings 2025 2025 2024 2024 Expiring within one year Expiring between two and five years Expiring in over five years 116,345 154,158 80.730 72,208 885,394 1,154,884 762,019 1.389,996 197,723 2,238,001 150,866 270,503 152,938 2,302,881 29. ContingentAssets In accordance with the SORP 2019 the tharity has recognised legacies when it is probable that it will be received. An agent is employed to notify the charity of bequests and a system of monitoring ensures that the legacy is tracked until rec&ipt. At the year end the charity had been notified of 55 legacies (2023124: 52) which had not met all the criteria for income recognition. These totalled approximately £3,125,196 (2023124.. £2,835,090) including 8 material legacies estimated at £2,220,000 (2023124: £2,385,000:(9)). 30. Capital Commitments At 31 March 2025 the charity had one capital commitment in relation lo the implementation of the EPOS system within retail amounting to £26,549. 31. Post Balance Sheet Events After the balance sheet date but before the approval of the statutory financial statements the charity made four redundancies with payments totsling £11.616. Tenovus Can¢er Care Annual Reports and Account5 Year Ended 31 March 2025 Comparative SOFA Financial Statements Consolidated Statement of Financial Activities for the year ended 31 March 2024 (incorporating income and expenditure account and stalement of recognised gains and losses). 80 Note Unreslricted Funds 2024 Restricted Funds 2024 Total 2024 Total 2023 INCOME & ENDOWMENTS FROM: Donations & Legacies Total Fundraising Income 3.082,085 180,599 3,262,684 2,145,517 3,082,085 180,599 3,262,684 2,145,517 Expenditure Raising funds- donations & legacies Totsl Fundraising Expenditure (1.097.649) {1,097,649) (1,057.686) 11,097,649) {1,097,649) (1.057,686) Fundraising Contribution Investment income Other income Total Conlributlon from Income & Endowments 1,984.436 180,599 2,165,035 1,087,831 115,066 14.109 2,113,611 115,066 14,109 2,294,210 114,541 92,246 1.294,618 180,599 Retsil Operations Trading Income Retail Operations Trading Expenditure Contribution from Retail Operations Other Trading Activities Income Other Trading Activities expenditure Contribution from Other Activities Total Contrlbutlon from Trading Activities 5,581,918 5,581,918 5,655,320 (5,137,977) (4,956) (5,142,933) (4,759,001) 443,941 (4.956) 438,985 896,319 665,753 11,566 677.319 608.808 {303,995) (303.995) (228,506) 361.758 11.566 373.324 380,302 805,699 6,610 812,309 1.276,621 Tenovus Cancer Care Annual Reports and Accounts Year Ended 31 March 2025 81 Consolidated Statement of Financial Activities for the year ended 31 March 2024 (incorporating income and expenditure account and statement of recognised gains and losses) continued Net income available for Charitable Activities 2,919,310 187,209 3.106,519 2,571,239 Charitable Expenditure Benefit Advisors Counselling Support Line Mobile Units Sing with Us Support Groups Research, Policy & Insi ht Community En ment Total Charitable Expenditure Net income before (loss)Igains on Investments 8a 8b 8c 8d 270,033 225,212 275.344 387,592 393.176 38,415 205.785 5,545 164,028 9,124 308,448 430,997 280,889 551,620 402.300 258,459 394.762 218,341 690,073 443,588 8f 200.108 200.108 254.928 8g 2.056 71,862 73.918 (1.753.521) (494.759) (2,248,280) 12,260,151) 1,165,789 {307.550) 858,239 311,088 Represented by Total Income Total Expenditure 9,458,931 {8,293,142) 192.165 (499,715) 9,651,096 (8,792,857) 8,616,432 {8,305,344) Net {loss)I gain on investments 16 400,935 400,935 (262,527) Net IncomelExpenditure Transfer between funds Gainsl(Losses) on disposal of fixed assets Net movement in fiJnds Reconciliation of funds Funds brought forward at 1 April 2023 Total funds carrled forward at 31 March 2024 1,566,724 (307.550) 1,259,174 48,561 29.406 (29,406) 13 6,000 6,000 (381) 1.602,130 (336,956) 1,265,174 48.180 22 6.487,293 1,063,525 7,550,818 7.502.638 22 8.089.423 726,569 8,815,992 7,550,818 The surplus foT th8 year for Companies Act purposes comprises th9 net incomellexpendilure} for the year of £1,259,174 (2Q2212023'. £48,561), with an additional gain of £6,0001202212023'. £38110ss} on disposal of fixed assets giving a nel surplus of £1,265,174 1202212023.. £48.180 surplus). There Is no tax payable on any of the activS1ies. The note5 on pages 52-81 fonn part of these financial stalem8nts. 2fee te IA$ We want to thank Community and Corporate Supporters 2024125 IOYFan 64 asthetics ACTTraining Adelora swimwear AdmiraL Allens Printers Afaly Graig Cider & Perry Angeni Support Asbri Golf AshmoLe & Co Bangor City Council Behind the Gate - Mr John 5aunders-Davies BMW Berlin Marathon Beaufort MVC Berry Smith SoLicitors Btaengwar Primary BNI Beacons Bois Y Bryn Brecon Careg Brian Lee Golf Academy Bluestone Btakemore Foundation CapeL Y Boro Conwy Town CounciL Cor y Boro Cardiff Beauty CLinic Castell HowelL The Celtic Manor Resort Cat SouthaLL Colwyn Bay Crematorium Co-op Community Fund Cor Meibion Co[￿n County Power Cwm Farm Clogau Coracle Coaches Cosmos Mexicana Corgi Daffodils Company Debbie Chapman Dancers Darren Tyson, Soloist Dragons RFC Eversheds Sutherland - Cardiff Branch Eve Carey, Soprano EVOL Wales Ewemoo FairHolme Preparatory School Football Association of WaLes FunctionaL 7 Gym Fussell Spirits FoLly Farm Gimme BaLLs Gin at 64 Grapevine Event Management Gwawr Edwards soLoist Glan Y Mor SchooL Hugh James HolLand House Irish Life Dublin Marathon Ironman WaLes Jones Bros Civil Engineering Uk Jayne Lloyd John Lewis Cardiff Jellyh'sh IT Solutions Llanrvvst Town Council LBS Building Merchants LG Networks and CiviLs Llandeilo Town 8usinesses and Community LlanelLi ScarLets Rugby CLub Lloyds Pharmacy ClinicaL Homecare LlangoLLen prostate cancer support group London Office of Welsh Government London St Davids Day Committee London WaLe5 Week London Welsh Centre London WeLsh Rugby CLub Marathon Eryri McArthur GLen Bridgend Moel Ellio Race Moorcroft ResidentiaL Care Home Natwest Cardiff Neuadd Goffa, LLanfairpwLLgwyngyll Number One ReaL Estate Physio Mon Par 59 Participating Free WILL Month soLicitors Peak Performance WaLes Penarth Town Council Penarth and Dinas Runners 83. Tenovus Cancer Care N.npual Report and A.ccoui"l-. ) | Yp&r Eiidin(J 31 Maich 2025 Rydym am ddiolch Charitable Trusts and Funders 2024125 PoweLLs of Prestatyn PLumbstop Print Sauce PrincipaLity Stadium Pure Cyber Queen Elizabeth High School Rogers Jones Auctioneers ReaU)uzz RLE Law Rockwood Sound Rose Graham, Harpist RPM Shopfronts S4C Heno sheeps And Leeks Snack Shack AF Soulfit Gym 5t Gerard's School St Andrews Reformed Ckyjrch Swansea Building Society Tanya Whitebits TCS London Marathon The Cardiff Half Marathon The Events Room The Plough Hotel and Restaurant The Spice Mix The Welsh Italian Pizza Company The Grain Ingredient The Willows Holistic Therapies Thomas Carroll Tiny Rebel Brewery Twr Y Felin HoteL Trainer Container Transport for Wales Travis George Tribe 517 United WorLdwide WOW training Welsh Brew Welsh Rugby Union Westmore Insurance White company Whiteheads Wild Water Babes YsgoL Y LLYS Bristol Myers Squibb Ceredigion Cynnal y Cardi UKSPF Community Grant Community and Voluntary Support Conwy UKSPF - Voluntary Sector Key Fund G M Morrison Charitable Trust Garfleld Weston Foundation Hartsheath CharitabLe Trust Hodge Foundation LocaLgiving MilLennium Stadium Charitable Trust National Lottery Awards for All Powys Church in Wales Act Fund RhyL Flat Community Benefit Fund Roche RockwooL UK Philanthropic Donations & Sponsorship Scottish Power Foundation Simon Gibson CharitabLe Trust St James's Place Charitable Foundation The Forest HILI CharitabLe Trust The G C Gibson Charitable Trust The Moondance Foundation The shaw Foundation Toyota Manufacturing UK Charitable Trust Wales Council for Voluntary Action: Volunteering Main Grants ipniwui Laip Ai".til i Roport I. ! A(counls l Yedi Eiiclir4g 31 Viarch 202J 84. Frxends of Tenovus Cancer Care Groups Patrons and celebrity supporters Aberdare Abergavenny Barry Bridgend Caidiff South Crofty Cwmbran Letterston/TreLetert LLandeilo and DinefiNr LLandudno LLandybie LLanidloes Merthyr Tydfil Morriston and Llangyfelach Pembrey and Burry Port Penparc Pontypridd Radyr and Morganstown Rhiwbina Ruthin and Denbigh Swansea Team Bertie Tenby A sincere thank you to all our Patrons and celebrity supporters incLuding: Asmaa AL-ALlak Brynmor Williams Dot Davies Emyr Gibson Fauve Birch Kate Lewis Kai Widdrington Katya Jones Matt Johnson Gerallt Pennant Sian LLoyd Tommy BLaze Tenows Cancer Care Ai)nual Repoit . | Year,. 1.131 Viarcl". 2025 èo/cL Tenovus Cancer Care, Jones Court, Womanby Street, Cardiff CFIO IBR. Gof3l Canser Tenows, Cwrt Jones: Stryd Womanby, Caerdydd CF101BR. 029 2076 8850 info@tenovuscancercare.org.uk tenovuscancercare.org.uk Regisiered Charity Number1054015 Company Limited by Guarantee Number 943501. ELusen Gofrestredig Rhif1054015 Cwmni Cytyngedig trvvy Warant Rhif 943501. FR tenovQ RÉGULATOii cancer care gofal canser R4EOLFIDol￿yp. qu¢fity ODI ARIAN